Target price: analyst consensus $75 (below current). Bull case at $100+ if UCT 3.0 executes and WFE hits 20%+ growth. Bear case at $40-50 if H2 2026 inflection slips.
Ultra Clean Holdings manufactures the critical subsystems and components that go inside semiconductor capital equipment. When a chipmaker buys a deposition or etch tool from Applied Materials or Lam Research, much of the fluid and gas delivery plumbing, the precision weldments, and the ultra-clean valves inside that tool came from UCT. UCT also runs a Services segment that cleans, recoats, and analytically tests the used components that come out of operating fabs — a consumable-like revenue stream tied to fab utilization rather than new equipment builds.
The company does not sell to chipmakers directly. Its customers are OEM equipment builders (Applied Materials, Lam Research, KLA, ASML), which makes UCTT a leveraged play on capital equipment spending rather than on any single chipmaker’s capex decisions.
| Field | Detail |
|---|---|
| Full legal name | Ultra Clean Holdings, Inc. |
| Ticker / Exchange | UCTT / NASDAQ |
| GICS Sector | Information Technology |
| GICS Industry | Semiconductor Equipment & Materials |
| HQ | Hayward, California, USA |
| Founded | 1991 |
| IPO | March 2004 (NASDAQ) |
| Website | uct.com |
| Employees | ~6,948 (as of 2025) |
| Segment | What It Does | FY2025 Revenue | % of Total |
|---|---|---|---|
| Products | Designs and manufactures critical subsystems: gas delivery modules, chemical delivery systems, fluid control, precision weldments, frame assemblies, robotics, process modules | $1,799M | 87.6% |
| Services | Ultra-high purity cleaning, recoating, and micro-contamination analysis of fab-used components | $255M | 12.4% |
Revenue model: Contract manufacturing and supply agreements with OEM equipment makers. Predominantly one-time sale on Products (correlated to WFE capital spending cycles); Services revenues are more recurring and correlated to fab utilization. Gross margins in Services (~30%) are roughly double Products (~14%), creating a margin mix lever.
The company generates revenue globally, closely mirroring the geographic footprint of its OEM customers’ manufacturing and customer support operations. Specific geographic revenue splits are not disclosed at a granular level in public filings, but the manufacturing base spans North America, Europe, and Asia-Pacific (Malaysia, Singapore, Thailand, South Korea, Taiwan, China, Japan, Philippines). New CEO James Xiao has announced a strategic initiative to increase Asia manufacturing from ~50% to ~60% of total capacity to be closer to customer fabs.
UCT Investor Relations Page — No standalone investor day deck found in the last 12 months. Most recent investor materials are embedded in Q4 2025 earnings slides and the 2024 10-K (filed March 2025). Link to the investor overview page above; specific earnings presentation PDFs available via the IR financials section.
UCT operates a highly distributed, asset-heavy manufacturing footprint across five continents — a deliberate design to co-locate with OEM customer manufacturing sites and avoid single-region concentration risk.
North America
| Location | Operations |
|---|---|
| Oregon (Hillsboro) | Sub-fab integration, components (acquired HIS Innovations, Oct 2023) |
| California | Chemical/gas delivery, system integration, thermal control, cleaning/coating |
| Arizona | Cleaning, coating, analytical testing, metal fabrication, system integration |
| Colorado | Cleaning and coating |
| Texas | Flow control, fluid management, instrumentation, chemical/gas delivery, weldments, cleaning |
| Ontario (Canada) | Flow control, fluid management, instrumentation |
| Maine | Cleaning and coating |
Europe
| Location | Operations |
|---|---|
| Scotland | Cleaning and coating |
| United Kingdom | Flow control, fluid management, gas/liquid control systems, instrumentation |
| France | Flow control, fluid management, gas/liquid control systems, instrumentation |
| Germany | Flow control, fluid management, instrumentation |
| Czech Republic | Precision machining, chemical/gas delivery integration |
| Ireland | Cleaning, coating, analytical testing |
| Netherlands | Fluid Solutions office |
Asia-Pacific and Middle East
| Location | Operations |
|---|---|
| Malaysia (Batu Kawan, Penang) | Precision machining, chemical/gas delivery integration (expansion site) |
| Singapore | Cleaning, coating, flow control, fluid management, system integration, 3D manufacturing, instrumentation |
| Thailand | Components manufacturing |
| South Korea | Control valves, flow control, fluid management, instrumentation, cleaning, coating |
| Taiwan | Cleaning, coating, analytical testing |
| China | Chemical/gas delivery, system integration, thermal control |
| Philippines | Chemical and gas delivery |
| Japan | Flow control, fluid management, instrumentation |
| Israel | Flow control, fluid management, instrumentation, cleaning, coating, analytical testing |
Asset map: no publicly available embed from IR materials. See the UCT Operations page for the current facilities overview.
Asset dynamics: UCT is asset-heavy relative to pure-play services companies, but asset-light relative to semiconductor fabs themselves. The physical footprint drives fixed cost overhead — when revenue dropped from $2.4B (FY2022) to $1.7B (FY2023), the facilities structure became a drag on margins. Conversely, with $3B of installed capacity running at ~65% utilization as of Q4 2025, incremental revenue growth should convert at high marginal operating leverage. Management has stated existing infrastructure can support $3B in revenue with minimal additional capex.
JVs: None disclosed in public filings.
Material partnerships: UCT’s commercial relationships are defined by deep supply agreements with its OEM customers — Applied Materials, Lam Research, KLA, and ASML — rather than formal JVs. These are strategic in practice: UCT designs and qualifies product platforms specifically to one customer’s tool architecture, creating high bilateral switching costs.
HIS Innovations Group (acquired Oct 2023): Previously a strategic supplier in the sub-fab integration segment (Hillsboro, Oregon). Now a wholly owned subsidiary.
| # | Customer | Ticker | Est. Revenue Share (FY2025) | Relationship Type |
|---|---|---|---|---|
| 1 | Lam Research | LRCX | ~33% | OEM supplier (subsystems for etch/deposition tools) |
| 2 | Applied Materials | AMAT | ~23% | OEM supplier (subsystems across etch, CVD, CMP tools) |
| 3 | KLA Corporation | KLAC | ~3-5% est. | OEM supplier (components for inspection equipment) |
| 4 | ASML | ASML | Undisclosed | OEM supplier (precision components) |
| 5 | Intel | INTC | Undisclosed; flagged as a key IDM customer | End-market IDM (tools bought by Intel contain UCT subsystems) |
Concentration risk: Applied Materials and Lam Research combined represented 58.7% of FY2025 revenue (down from 64.0% in FY2021, 62.7% in FY2022, 57.4% in FY2023, 54.5% in FY2024). The top three customers (adding KLA) historically approached 70-80% of revenue. Single-customer concentration is extreme — loss of AMAT or LRCX as a customer would be a company-defining event.
Dependency flags: - Both AMAT and LRCX are customers and, to a degree, competitive in certain subsystem categories (large OEMs occasionally insource). No public evidence of active insourcing threat, but the structural dynamic exists. - Intel (INTC) is flagged as a key IDM customer whose fab ramp (18A process, Fab 34 Ireland, Ohio fab) is a demand catalyst. UCT does not sell directly to Intel but benefits as Intel ramps equipment purchases from AMAT/LRCX.
Modern semiconductor manufacturing tools operate at atomic-scale precision. The gas delivery systems, fluid control modules, and ultra-clean components that manage the flow of reactive chemicals inside these tools must perform to tolerances measured in parts per trillion of contamination. Getting these subsystems wrong means defective chips and expensive tool downtime. UCT has spent 30+ years qualifying its components into the production processes of the world’s largest equipment makers — a qualification process that takes years and is nearly impossible to replicate quickly. In a world building AI data centers at record pace and scrambling to onshore semiconductor manufacturing, every new fab and every new tool order creates demand for UCT’s subsystems.
UCT’s products serve semiconductor capital equipment for the following processes: - Etch (Lam Research TEL tools): gas delivery, plasma confinement components - CVD/ALD/PVD (Applied Materials, Tokyo Electron): chemical delivery, fluid control - CMP (Applied Materials): slurry delivery, fluid management - Cleaning (Lam Research SAPS/MSAP, TEL): fluid systems - Inspection/metrology (KLA): precision components - Advanced packaging (BESI, AMAT Ensemble): sub-fab integration, fluid systems - Sub-fab (pumps, abatement, utilities): HIS Innovations segment (Oregon)
| Metric | Estimate | Source |
|---|---|---|
| Global WFE market (FY2025) | ~$100-110B | SEMI / analyst consensus |
| UCT addressable subsystem market (est.) | ~$12-19B | Industry estimates |
| UCT revenue (FY2025) | $2.05B | Company reported |
| Implied market share | ~10-15% of subsystem TAM | Analyst estimates |
| Name | Title | Tenure | Background |
|---|---|---|---|
| James Xiao | CEO and Director | Since Sep 2025 | 30+ years in semiconductor/display/solar. Spent 19 years at Applied Materials as Corporate VP and GM of semiconductor products group. Also served as President of Applied Films China. B.S. Applied Physics (Dalian), MBA (Indiana/Kelley), Stanford exec training. Deep operational credibility in the OEM ecosystem UCT serves. |
| Sheri Savage | CFO (SVP Finance) | Since 2016 | Prior Corporate Controller at Credence Systems. Earlier roles at Protiviti, KLA-Tencor, Arthur Andersen. B.S. Managerial Economics (UC Davis). Long tenure at UCT; institutional knowledge of the business. |
| Robert Wunar | COO | Since Mar 2026 | 30+ years in semiconductor equipment operations. Joined from Applied Materials where he was COO/Managing Director overseeing revenue and supply chain. Prior: HelmSmart Consulting, SolarCity. B.S. Electronics Engineering (DeVry). Very recent hire — execution track record at UCT not yet established. |
| Chris Cook | Chief Business Officer | Since Aug 2025 (at UCT since Apr 2022) | 25 years at semiconductor companies: Renesas, Infineon, Flex, Cypress Semiconductor. B.S. Electrical Engineering (Purdue), Harvard Business School Leadership Development. |
| Jeff McKibben | CIO | Since 2021 | 30+ years in high-tech manufacturing IT. Previously CIO at ON Semiconductor ($6B). Earlier at HP. M.S. MIS (University of Arizona), B.S. Humanities/IR (Georgetown). |
| Jamie Palfrey | CHRO | Not specified | 25+ years leading global HR. Prior: Shape Technologies, FEI Company, Lam Research, ConocoPhillips. |
Management transition note: UCT underwent significant C-suite turnover in 2025. The previous CEO (Clarence Granger, who was also the founding executive) stepped down. James Xiao (Sep 2025), Robert Wunar (Mar 2026), and Chris Cook (Aug 2025) are all new to their current roles. This is a complete reset of the operating leadership. Key risk: execution risk is elevated until the new team establishes a track record.
| Name | Role | Independent? | Background | Committee Seats |
|---|---|---|---|---|
| Tom Edman | Chairman (effective May 2026) | Yes | CEO of TTM Technologies (TTMI). Former Group VP at Applied Materials; was President/CEO of Applied Films (acquired by AMAT 2006). B.A. East Asian Studies (Yale), MBA (Wharton). Deep semiconductor equipment domain expertise. | Nominating/Governance |
| Clarence Granger | Director (stepping down as Chairman May 2026) | No (former CEO) | Founded UCT; served as CEO for 12 years. Prior: Seagate Technology, HMT Technology. B.S. Industrial Engineering (UC Berkeley), M.S. IE (Stanford). Exiting Chairman role. | N/A |
| David ibnAle | Director | Yes | Founding/Managing Partner of Advance Venture Partners. Previously Augusta Columbia Capital Group, TPG Growth. 20+ years in tech investment. B.A./M.A. Public Policy/International Development (Stanford), MBA (Stanford GSB). | Compensation |
| Emily Liggett | Director | Yes | CEO of Liggett Advisors. Former CEO roles: NovaTorque, Apexon, Capstone Turbine, Elo TouchSystems. B.S. Chemical Engineering (Purdue), M.S. Mfg Systems (Stanford), MBA (Stanford). | Compensation |
| Ernest Maddock | Director | Yes | Retired SVP/CFO of Micron Technology. Earlier EVP/CFO at Riverbed Technology, 15 years at Lam Research rising to EVP/CFO. B.S. Industrial Management (Georgia Tech), MBA (Georgia State). | Audit (likely Chair) |
| Jackie Seto | Director | Yes | Principal at Side People Consulting. 22 years at Lam Research, reached Group VP and GM of Clean Business Unit. | Nominating/Governance |
| Joanne Solomon | Director | Yes | Joined Feb 2025. 35+ years financial leadership. CFO at Amkor Technology for 9 years. Former Audit Senior Manager at Price Waterhouse. Board: Viavi Solutions. B.S. Business/Accounting (Drexel), MBA (Thunderbird/ASU). | Audit |
Board quality: Strong domain depth — Edman (Applied Materials/TTM Technologies), Maddock (Lam Research/Micron), and Seto (Lam Research) collectively bring decades of semiconductor equipment and fab experience directly relevant to UCT’s business. Board transition underway with Granger stepping down; Edman as incoming Chair is an upgrade in terms of active industry engagement.
| Competitor | Ticker | Overlap | Notes |
|---|---|---|---|
| Ichor Holdings | ICHR | High — nearly identical business model | Closest pure-play comp. Makes gas/fluid delivery subsystems for semiconductor OEMs. Smaller revenue base (~$1B). |
| MKS Instruments | MKSI | Partial — overlaps in gas/fluid control; MKS is broader | Offers power delivery, vacuum, and process control in addition to gas delivery. More diversified. |
| Advanced Energy Industries | AEIS | Partial — power delivery/thermal | Adjacent in thermal management; less direct in fluid/subsystem manufacturing. |
| Entegris | ENTG | Partial — overlaps in materials/contamination control | Stronger in specialty chemicals and filtration; Services segment overlaps in contamination analysis. |
| Sanmina / Plexus | SAN / PLXS | Partial — contract manufacturing overlap | Broader contract manufacturers; less semiconductor-specialized. |
UCT’s durable advantages: - Qualification barriers: Subsystems are qualified into specific OEM tool platforms over 12-24 month processes; re-qualification of a new supplier is expensive and time-consuming for OEMs. This creates sticky bilateral lock-in. - Co-location: Manufacturing proximity to OEM facilities reduces lead times and enables rapid design iteration; building this network takes years. - Engineering depth: UCT has deep applications engineering embedded in customer programs — it’s a design partner, not just a box-builder. - Scale: At $2B+ in revenue, UCT has procurement leverage on raw materials and can absorb qualification costs better than smaller competitors.
| Force | Assessment |
|---|---|
| Supplier power | Moderate. UCT sources specialty metals, fittings, valves from a supply base that includes some concentration. Tariff exposure has been mostly recoverable (~90%). |
| Buyer power | High. AMAT and LRCX together represent ~57% of revenue and have meaningful pricing leverage. They can insource, dual-source, or put pressure on UCT’s margins. |
| Competitive rivalry | Moderate. Ichor is the closest pure-play competitor. However, OEM program relationships are sticky, making direct head-to-head competition on existing platforms relatively rare. |
| New entrant threat | Low-to-moderate. High qualification barriers protect incumbents. However, OEMs in theory can develop internal capabilities (insourcing risk). |
| Substitution | Low. No alternative to precision fluid/gas delivery subsystems exists for semiconductor manufacturing tools. The form factor may change (advanced packaging vs. traditional deposition), but UCT’s capabilities are adaptable. |
Valuation (as of ~April 24, 2026)
| Metric | Value |
|---|---|
| Market cap | ~$3.78B |
| Enterprise value | ~$3.95B (est., market cap + net debt ~$165M) |
| P/E (TTM, GAAP) | N/A (net loss FY2025 due to goodwill impairment) |
| Forward P/E (FY2026E) | ~42x (on consensus EPS $2.01) |
| EV/EBITDA | Not calculated; EBITDA approx. $100M TTM non-GAAP; EV/EBITDA ~40x |
| FCF yield | ~0.4% (FCF $15M TTM / market cap $3.78B) |
| Dividend yield | None |
| 52-week range | $18.02 - $84.43 |
Note: Stock up ~277% from April 2025 lows (~$20). Valuation has re-rated significantly.
Income Statement and Margins
| Metric | FY2022 | FY2023 | FY2024 (FY0) | FY2025E (consensus) |
|---|---|---|---|---|
| Revenue | $2,374M | $1,735M | $2,098M | $2,054M (actual) |
| Revenue growth YoY | +12.9% | -26.9% | +20.9% | -2.1% |
| Gross profit | $465M | $277M | $356M | $323M |
| Gross margin | 19.6% | 16.0% | 17.0% | 15.7% |
| EBIT | $120M | $35M | $91M | -$107M |
| EBIT margin | 5.1% | 2.0% | 4.4% | -5.2% |
| Net income | $40M | -$31M | $24M | -$181M |
| Net margin | 1.7% | -1.8% | 1.1% | -8.8% |
| EPS (diluted) | $0.88 | -$0.70 | $0.52 | -$4.00 |
| Non-GAAP EPS | N/A | $0.56 | $1.44 | $1.05 |
FY2025 net loss driven entirely by a $151.1M non-cash goodwill impairment charge. Non-GAAP net income was $47.7M.
Forward Consensus Estimates
| Metric | FY2026E | FY2027E |
|---|---|---|
| Revenue | $2,454M (+19%) | $2,870M (+17%) |
| EPS (diluted) | $2.01 | $3.51 |
| Forward P/E | ~42x | ~24x |
Cash Flow and Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | $47M | $136M | $65M | $66M |
| Capex | -$100M | -$76M | -$64M | -$50M |
| Free cash flow | -$53M | $60M | $2M | $15M |
| FCF margin | -2.2% | 3.5% | 0.1% | 0.7% |
| Cash | $359M | $307M | $314M | $312M |
| Total debt | $611M | $640M | $660M | $654M |
| Net debt | $252M | $333M | $346M | $342M |
| Net debt / EBITDA | N/A | ~5x | ~2.5x | N/A (negative EBITDA GAAP) |
| ROIC | Low single digits | Negative | Low single digits | Negative |
Net debt figures shown as absolute (debt minus cash). The business generates modest FCF at current utilization but has meaningful leverage. Debt-to-equity is manageable given balance sheet equity of $711M.
WFE cycle recovery following a sharp 2023 trough. The industry saw a ~$10B WFE decline in 2023; UCT’s revenue fell 27% that year. The 2024 recovery (+21% revenue) showed the operating leverage on the upside. Management expects 15-20% WFE growth in FY2026, with UCT targeting above-market outperformance through market share gains and product mix improvements.
UCT 3.0 strategic initiative: New CEO Xiao has reorganized the company around operational execution, margin recovery, and ramp-readiness. Key pillars: 1. Increase Asia manufacturing share from 50% to 60% (proximity to customer fabs) 2. Fluid Solutions product qualification completing H1 2026 — should improve Services margin mix 3. Sub-fab segment (HIS/Oregon) growing as fabs require more integrated sub-fab solutions 4. Advanced packaging demand: CoWoS and heterogeneous integration tool sets require UCT’s precision subsystems
Capacity utilization thesis: UCT currently operates at ~65% of installed capacity, which is sized to support $3B in revenue. Every percentage point of utilization recovery above the current baseline drives high-margin incremental revenue with minimal new capex required. This is the core of the “available capacity upside” thesis.
Intel 18A and fab ramps: Intel buying equipment from AMAT and LRCX for 18A production ramp (Fab 34 Ireland, Ohio, Arizona) directly drives UCT order flow. Intel has received $8.9B in US government equity investment to support domestic fab buildout — a multi-year equipment procurement cycle.
Memory upcycle: AI-specific HBM demand growing at 22% CAGR per management. NAND upgrades (higher layer counts) require new tool sets. Both drive UCT subsystem demand through Lam Research and other etch/deposition OEMs.
| Risk | Likelihood | Existing Mitigants | Management De-risk Plan | Can It Be Closed? |
|---|---|---|---|---|
| Customer concentration (AMAT/LRCX ~57% of revenue) | High — structural | Multiple OEM relationships; growing IDM and advanced packaging exposure | Diversify revenue mix toward emerging OEMs (ASML, KLA) and IDMs; Fluid Solutions into new customer programs | No — structural to the business model; can be reduced but not eliminated |
| WFE cyclicality | High — structural | Services segment (~12% revenue) partially counter-cyclical; cash buffer of $312M | Maintain lean cost structure; utilization-based scaling; Services as stabilizer | No — semiconductor capex cycles are inherent; UCT will always track WFE |
| Management transition execution risk | Medium-High | Deep bench of semiconductor industry veterans; board stability | Xiao/Wunar/Cook all have deep domain experience from Applied Materials and peer OEMs; UCT 3.0 provides a structured execution framework | Partially — closes as the new team demonstrates results over 2-4 quarters |
| Tariff/trade policy risk | Medium | ~90% tariff cost recovery from customers; distributed manufacturing footprint reduces single-country exposure | Asia manufacturing expansion insulates from US-China tariffs; ongoing tariff recovery process | Partially — recovery mechanism addresses economics; geopolitical risk remains open |
| Goodwill and asset impairment | Low-Medium | $151M impairment taken in FY2025; goodwill balance reduced | Balance sheet cleaned up; future impairment risk reduced but not zero as new acquisitions are integrated | Partially — one-time event, unlikely to recur at same magnitude absent new acquisitions |
James Xiao (CEO) is new to the role (September 2025) and is the architect of the UCT 3.0 turnaround. His Applied Materials background is directly relevant and is a key reason the market re-rated the stock. Formal employment agreement terms not extracted from public filings. The entire executive team is new (Xiao, Wunar, Cook all appointed 2025-2026) — key-person risk is diffuse across the leadership layer rather than concentrated in one individual.
Last earnings: Q4 2025, reported February 23, 2026. - Q4 revenue $506.6M vs. $563M a year prior; full-year 2025 revenue $2,054M - $151.1M non-cash goodwill impairment drove GAAP net loss of $181.2M for the year - Non-GAAP EPS for FY2025 was $1.05; for Q4 was $0.22 - Gross margin compression: 15.7% for FY2025 vs. 17.0% in FY2024 - Q1 2026 guidance: $505-545M revenue, non-GAAP EPS $0.18-$0.34 - Management raised WFE growth outlook to 15-20% for FY2026 - CEO Xiao announced AI-focused Asian capacity plan (50% to 60% Asia manufacturing)
Next earnings: Q1 2026 results expected late April / early May 2026.
Material news (last 90 days): - March 2026: Robert Wunar appointed COO (effective March 23, 2026) - April-May 2026: Board Chair transition — Clarence Granger stepping down May 22, 2026; Tom Edman appointed as incoming Chairman - April 2026: Stock up ~202% year-to-date (from ~$20 lows in April 2025 to ~$83 in April 2026) - WFE spending optimism from AI infrastructure buildout driving sector re-rating
| Holder | Type | Who They Are | Shares | % Outstanding | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | Institutional — passive index | World’s largest asset manager; holds UCT via index and active strategies | 6,719,452 | 15.0% | 13F |
| Vanguard Group | Institutional — passive index | Second-largest asset manager; index inclusion | 4,990,724 | 11.0% | 13F |
| Frontier Capital Management | Institutional — active growth | Boston-based active small/mid-cap growth manager; specialist in tech and industrial growth names | 3,509,839 | 7.7% | 13F |
| Invesco Ltd. | Institutional — passive/active mix | Global asset manager; likely via ETF products including sector and mid-cap ETFs | 3,399,834 | 7.5% | 13F |
| State Street Corp | Institutional — passive index | Index and ETF manager (SPDR funds); broad index inclusion | 1,852,482 | 5.0% | 13F |
| Dimensional Fund Advisors | Institutional — quantitative | Factor-based quant manager; holds small/mid-cap value/growth factor exposure | 1,524,857 | 3.4% | 13F |
| Royce & Associates | Institutional — active small-cap | Small-cap specialist value manager; long-term holders of semiconductor equipment names | 1,098,693 | 2.4% | 13F |
Total institutional ownership: ~94% of shares outstanding (244 institutional owners, 238 long-only, 5 long/short). High institutional ownership reflects a well-covered small-cap name with significant index inclusion. Frontier Capital at 7.7% is the largest active thesis-driven holder — their continued conviction is worth tracking.
Insider ownership: Low in percentage terms given the ~94% institutional float. Founder Clarence Granger remains a holder. Cross-check Form 4 filings for current insider levels.
Activist positions: None identified.
Short interest: Specific current short interest data not pulled from NASDAQ filings; check real-time. With the stock up ~280% from its 2025 lows, short squeeze dynamics have likely already played through, but short interest as % of float warrants monitoring at elevated valuation levels.
Recent ownership changes: Institutional holdings data current as of Feb-Apr 2026. No major disclosed position changes found in search results.
| Analyst | Firm | Rating | Price Target |
|---|---|---|---|
| Krish Sankar | TD Cowen | Strong Buy | $70 |
| Edward Yang | Oppenheimer | Buy | $85 |
| Charles Shi | Needham | Strong Buy | $70 |
Consensus: 3 analysts, all Buy/Strong Buy. Average price target: $75. Current price ~$83 — stock has run slightly past near-term consensus targets. Coverage is thin (3 analysts) — this is typical for a small-cap at this market cap tier and presents information edge for investors willing to do primary research. Consensus estimates carry less statistical weight with only 3 analysts.
The 2024 Form 10-K (filed March 2025) was accessed. Key data points incorporated: - Segment revenue (Products/Services) verified from 10-K - Customer concentration (AMAT/LRCX percentages) sourced from 10-K disclosures - The FY2025 10-K would be the next filing to monitor (expected March 2026 filing) for updated customer concentration, debt covenants, and goodwill balance post-impairment. - Recommend pulling current Form 4 insider transactions and any 13D/13G changes directly from EDGAR for the most current ownership data.
Sources: Ultra Clean Holdings IR (uct.com), PRNewswire earnings releases, StockAnalysis financials, Fintel institutional holdings, UCT Operations page, management bios from uct.com/about-uct/leadership, analyst consensus from StockAnalysis/TipRanks, Simply Wall St news, Yahoo Finance Q4 2025 earnings highlights.
Semiconductor capital equipment subsystems is adjacent to but distinct from “SiP/OSAT/RF” (covered April 20) and “Compound Semiconductor Equipment” (February 23). No direct prior primer for this sub-layer. Proceeding with the write-up; the subsystems layer is explained from first principles in Part I below.
Thesis: UCT is the canonical “picks and shovels” play inside the semiconductor capital equipment supply chain. It manufactures the critical fluid delivery, chemical handling, and precision subsystems that go inside AMAT and Lam Research tools — not the tools themselves. At 65% capacity utilization against infrastructure sized for $3B in revenue, every percentage point of WFE recovery drives high-margin incremental revenue with near-zero marginal capex. The Intel 18A ramp, AI-driven advanced packaging demand, and a multi-year memory upcycle create a structural demand backdrop for WFE in 2026 and beyond. A new management team from Applied Materials (CEO Xiao, COO Wunar) brings operational credibility and the UCT 3.0 strategic reset.
The tension: the stock has already re-rated 280% from April 2025 lows and sits at ~42x FY2026E earnings. The bull case requires the H2 2026 WFE inflection to arrive on schedule and UCT’s new management to execute. The bear case is a WFE slip, margin disappointment, or re-rating compression back toward 20x.
| Metric | Value |
|---|---|
| Current price | ~$83 (April 24, 2026) |
| Market cap | $3.78B |
| Enterprise value | $4.12B |
| FY2026E revenue consensus | $2.45B |
| FY2026E EPS consensus | $2.01 |
| Forward P/E | ~42x |
| Conviction level | Medium — thesis is sound, timing is post-re-rating |
Target price: analyst consensus $75 (below current). Bull case at $100+ if UCT 3.0 executes and WFE hits 20%+ growth. Bear case at $40-50 if H2 2026 inflection slips.
See /profile UCTT for full corporate identity.
Summary:
What it does in plain language: When an equipment maker like Applied Materials or Lam Research builds a chip-making tool, that tool needs a nervous system — miles of precision tubing, valves, gas delivery modules, chemical handling systems, and fluid control components that route highly reactive materials to the reaction chamber without contamination. UCT designs and builds that nervous system. It also runs a Services business that cleans and restores the used components that come out of operating fabs, a more consumable-like revenue stream.
Segments:
| Segment | Revenue FY2025 | % Total | Gross Margin |
|---|---|---|---|
| Products (subsystems/components for OEM equipment) | $1,799M | 87.6% | ~14% |
| Services (cleaning, recoating, contamination analysis) | $255M | 12.4% | ~30% |
Business model: Contract manufacturing supply agreements with OEM equipment makers. Revenue is project-based (Products) and quasi-consumable (Services). The Products segment tracks WFE capex cycles closely; Services is more stable and tracks fab utilization. This mix creates a natural partial hedge, though at 12% of revenue, Services is not large enough to insulate materially from WFE downturns.
Geographic revenue mix: Global, mirroring OEM customer manufacturing footprint. New CEO shifting Asia manufacturing from 50% to 60% of total to reduce costs and co-locate with customer fabs. No single-region revenue concentration disclosed.
Semiconductor manufacturing is an atomic-precision exercise. Building a modern chip requires depositing, etching, and cleaning material layers that are as thin as a few atoms. Every one of the hundreds of steps in a chip’s manufacturing flow requires precise delivery of specialty gases (silane, WF6, NF3, HCl, among many others) and ultra-pure chemicals (hydrogen peroxide, HF, TMAH, and various solvents) to the reaction chamber at controlled flow rates, pressures, temperatures, and concentrations.
The critical challenge: any contamination, any particle larger than a few nanometers, any variation in gas mix or pressure during a deposition or etch step will produce a defective chip. At 3nm and below, the tolerances are sub-angstrom. Getting even a few parts per billion of the wrong molecule into the chamber at the wrong moment can ruin a wafer worth $10,000 to $20,000.
Before specialized subsystem suppliers like UCT, OEM equipment makers (AMAT, Lam, TEL) built these fluid delivery systems in-house. The problem: it was expensive, slow, and not their core competency. UCT’s founding insight, developed by Clarence Granger and team in 1991, was that fluid delivery subsystems could be outsourced — and that a specialist with dedicated engineering and ultra-clean manufacturing could do it better and cheaper than the OEMs building it themselves. This was the birth of the semiconductor subsystem outsourcing model.
Why gases and chemicals matter: Chip manufacturing uses four main families of gas/chemical processes:
Chemical Vapor Deposition (CVD/ALD): Precursor gases react at the wafer surface to deposit thin films. Example: silane (SiH4) + oxidant → silicon dioxide film. The gas must arrive at exactly the right temperature, pressure, and concentration or the film has wrong thickness or uniformity.
Etch (dry/wet): Reactive gases (fluorine-based, chlorine-based) or liquid chemicals remove material selectively through photomask patterns. Flow rate and timing determine etch depth and selectivity.
Cleaning (dry and wet): After each process step, the wafer and chamber must be cleaned of residues. Ultra-pure water, HF, hydrogen peroxide and other chemicals remove particles and films at nanometer precision.
Purge and transition: Between process steps, chambers must be purged with inert gases (N2, Ar) to prevent cross-contamination.
Why ultra-high purity matters: At sub-10nm nodes, a single particle of 10nm or larger is lethal to the device being built. The gas delivery hardware must be manufactured to “ultra-high purity” (UHP) standards: internal surfaces electropolished to Ra <0.25 micrometers, all welds performed under inert atmosphere, no organic contamination above parts-per-trillion levels.
Key materials and components in UCT’s products: - Stainless steel tubing and fittings: Electropolished 316L SS for gas lines - PVDF, PFA, PP plastic tubing: For chemical delivery (resistant to HF, H2O2) - Mass flow controllers (MFCs): Measure and control gas flow at sccm-level precision - Pressure transducers, regulators: Maintain precise operating pressures - Pneumatic and manual valves: Control gas routing through manifolds - Component heaters: Maintain temperature stability along gas lines to prevent condensation of high-vapor-pressure precursors - Weldments: The welded stainless steel structural assemblies that form the skeletal frame of an OEM tool
A typical UCT gas delivery module goes through this sequence:
Design and Engineering: UCT receives tool platform specifications from AMAT or LRCX. Applications engineers design the gas delivery module layout — routing, valve positions, heater zones, flow paths — typically using CAD tools and flow simulation.
Component Sourcing: UCT sources MFCs (from Horiba, MKS Instruments, Brooks Instrument), valves (Swagelok, Fujikin, Parker), fittings (Swagelok), and tubing. Key suppliers are concentrated — MKS and Horiba are the dominant MFC suppliers globally.
Orbital Welding: Stainless steel tubing and fittings are joined using automated orbital TIG welding under argon blanket. UCT trained and certified its welders to the UHP welding standards required for semiconductor applications. A leaking or contaminated weld fails the entire assembly.
Cleaning: All components go through multi-stage ultrasonic cleaning, passivation (acid treatment to remove surface iron and promote chromium oxide layer), followed by cleanroom purging.
Assembly: Components assembled in ISO class 100 (Class 10) cleanrooms. All assembly personnel gowned; assembly under nitrogen or clean-air positive pressure.
Test and Verification: Helium leak test (finds leaks down to ~10^-10 mbar·L/s), residual gas analysis (RGA) to verify internal atmosphere cleanliness, electrical permeability tests on heater elements.
Packaging and Delivery: Modules nitrogen-purged, sealed in double-bagged cleanroom packaging, shipped to OEM’s assembly facility where they are integrated into the tool frame.
Where the hardest engineering challenges are:
| Metric | Why It Matters | State-of-Art |
|---|---|---|
| Surface roughness (Ra) | Smooth inner surfaces prevent particle generation and adsorption | <0.25 μm for UHP lines |
| Helium leak rate | Confirms hermetic integrity — any leak = contamination | <10^-10 mbar·L/s |
| Particle count (per weld) | Post-weld particle measurement in cleanroom | <10 particles >0.3μm per weld |
| RGA cleanliness | Residual moisture, hydrocarbons inside gas panel | H2O <50 ppb; THC <10 ppb |
| Flow uniformity | Across multi-zone delivery — critical for wafer uniformity | <±1% across zones |
| Qualification cycle time | How long it takes OEM to qualify a new UCT design into production | 12-24 months typical |
Investor tracking metric: qualification pipeline additions. If UCT is winning design-ins on new tool platforms (AMAT’s Centura Sculpta, LRCX’s Vantex etch tools), these are multi-year revenue streams. Design-win announcements and OEM tool launch timelines are the leading indicator.
Sub-categories:
| Product | What It Does | Customer | Revenue Contribution |
|---|---|---|---|
| Gas Delivery Modules (GDM) | Routes specialty gases from supply point to reaction chamber; contains valves, MFCs, pressure controls, heaters | AMAT (etch, CVD, CMP), LRCX (etch, CVD) | Largest single product category |
| Chemical Delivery Modules (CDM) | Routes liquid chemicals (HF, H2O2, solvents) in plastic-tubing systems; includes pumps, flow meters, cabinets | LRCX (wet clean), AMAT (CMP slurry) | Significant; Services overlap with cleaning |
| Frame Assemblies and Weldments | Structural frames and welded sub-assemblies that form the chassis of OEM tools; large-format metal fabrication | All major OEMs | High volume, lower margin |
| Fluid Solutions (valves, fittings, instrumentation) | Branded fluid control products: valves, connectors, pressure gauges, actuators, gas line heaters — primarily from UCT’s Fluid Solutions group (legacy acquisitions in Europe) | Broad including specialty gases, pharma | Growing; margin higher than frame assembly |
| Precision Robotics and Process Modules | Robotic wafer handling and process module integration | AMAT, TEL | Smaller but growing with advanced packaging |
| Sub-fab Integration (HIS Innovations, Hillsboro OR) | Design, manufacturing, integration of sub-fab components — pumps, abatement systems, utilities — the infrastructure below the fab floor | IDMs (Intel, TSMC customer bases indirectly) | Newer; growing with domestic fab buildout |
Key pricing dynamics: UCT’s Products are cost-plus in character — UCT prices to OEM customer specifications with a margin on top. OEMs have pricing leverage (UCT is a captive supplier in practice), but qualification barriers prevent frequent re-pricing events. Tariff cost recovery (~90%) is contractually embedded.
ASPs: Gas delivery modules for major etch and CVD tool platforms range from $50K to $500K+ per module depending on complexity. Frame assemblies may be lower; Fluid Solutions components are sold individually.
UCT’s Services business was built through acquisitions (QuantumClean and ChemTrace in 2018, $342M deal) and provides:
Why Services matters: At ~30% gross margin vs. ~14% for Products, Services is the margin engine. It is also more stable — it tracks fab utilization (wafers being processed) rather than capital equipment orders. During the 2023 WFE downturn, Services revenue held better than Products. Growing Services as a % of total is a margin lever management can pull. The Fluid Solutions qualification (completing H1 2026) is expected to add to this margin mix.
[Specialty Chemicals / Gases] → [Components (MFCs, Valves, Fittings)] → [★ UCT: Subsystems / Gas Delivery / Frame Assembly] → [OEM Equipment (AMAT, LRCX, KLA, TEL)] → [Chipmakers (TSMC, Intel, Samsung, Micron)] → [End Devices]UCT sits in the subsystems/components layer, one step below the OEM equipment makers and two steps below the chipmakers. This position has important implications:
Layer consolidation: The subsystems layer is oligopolistic — UCT and Ichor Holdings (ICHR) are the two dominant US-listed pure plays. Entry requires deep semiconductor domain expertise, UHP manufacturing capabilities, and OEM qualification that takes years to establish. New entrants are rare.
| Supplier | Ticker | Layer | Bypass-ability | Supplier MC vs UCTT | Market-pricing |
|---|---|---|---|---|---|
| MKS Instruments (MFCs, gas delivery components) | MKSI | Components | Partial — multiple MFC suppliers (Horiba, Brooks) but MKSI is largest | ~$5.5B vs $3.8B (1.5x larger) | Priced-in |
| Swagelok / Parker Hannifin (fittings, valves) | Private / PH | Components | Yes — multiple fitting suppliers | Swagelok private; PH ~$78B | Under-priced relative to role |
| Horiba (MFCs, flow control) | 6856.T | Components | Partial — competes with MKSI and Brooks | ~$6B | Priced-in |
| Specialty steel suppliers (316L SS tubing) | Various | Raw material | Yes — commoditized | N/A | Commodity |
Bottleneck verdict: No single UCT supplier is a hard bottleneck for the investment thesis. MKS Instruments is the closest thing to a captive supplier in MFCs, but there are three major competitors. The subsystem-layer bottleneck is UCT and ICHR themselves — they are the bottleneck between components and OEM tools, not their upstream.
| # | Customer | Ticker | Est. Revenue Share | Relationship Type | Contract Details |
|---|---|---|---|---|---|
| 1 | Lam Research | LRCX | ~33% | OEM supplier — subsystems for etch/deposition tools | Long-term supply agreements; UCT qualified into multiple Lam tool platforms |
| 2 | Applied Materials | AMAT | ~23% | OEM supplier — subsystems across etch, CVD, CMP, advanced packaging | Largest OEM customer; UCT designs embedded in AMAT tool platforms for 30+ years |
| 3 | KLA Corporation | KLAC | ~3-5% est. | OEM supplier — precision components for inspection tools | Smaller relationship; historically part of the “top 3 = 80% of revenue” figure |
| 4 | ASML | ASML | Undisclosed | OEM supplier — precision components for EUV/DUV systems | Growing relationship; ASML’s EUV tools require UHP components |
| 5 | Intel (indirect) | INTC | Undisclosed | IDM — Intel equipment purchases from AMAT/LRCX contain UCT subsystems | Intel is a demand catalyst via OEM, not a direct customer |
Lam Research (LRCX) — deeper profile: LRCX is UCT’s largest single customer at ~33% of revenue. Lam is the world’s leading etch equipment company with >50% share in CVD applications and strong deposition share. In FY2025, LRCX reported $16.7B in revenue. LRCX is financially strong, growing, and committed to serving the memory upcycle (HBM, NAND) and advanced logic (GAA). The relationship is mature and stable; design-win momentum in LRCX’s next-generation Vantex etch platform would be a positive signal.
Applied Materials (AMAT) — deeper profile: AMAT is the largest semiconductor equipment company globally (~$28B revenue in FY2025). AMAT is UCT’s second-largest customer at ~23% of revenue. AMAT’s breadth — CVD, PVD, etch, CMP, advanced packaging — gives UCT broad exposure across tool categories. CEO Xiao’s 19-year tenure at AMAT gives UCT an advantage in maintaining and deepening this relationship.
Concentration risk assessment: Top-2 customers represent ~56-57% of revenue. If AMAT walked away tomorrow, UCT would lose ~$470M in annual revenue — roughly 23% of the total. That would be company-defining. The structural concentration is the single largest risk in the thesis. There is no quick fix, as revenue diversification requires winning on new platforms that take 2-4 years to qualify.
Why it matters: Every semiconductor fab tool ordered by TSMC, Intel, Samsung, or Micron requires UCT-style subsystems. There is no alternative delivery mechanism for the reactive gases and chemicals that enable chip manufacturing. UCT’s subsystems are the plumbing that makes chip manufacturing physically possible.
End-use applications:
| Application | Tool OEM | UCT Role |
|---|---|---|
| Logic (3nm, 2nm, 18A) etch | LRCX, TEL | Gas delivery modules, frame assemblies |
| ALD/CVD for gate-all-around (GAA) | AMAT, TEL | Chemical delivery, gas panels |
| CMP (planarization) | AMAT | Slurry delivery, fluid management |
| Wet clean | LRCX (SAPS/MSAP), TEL | Chemical delivery, fluid systems |
| Advanced packaging (CoWoS, SoIC, EMIB) | AMAT (Ensemble), BESI | Precision subsystems, fluid systems |
| HBM/NAND etch and deposition | LRCX, TEL | Gas delivery, process modules |
| Sub-fab (pumps, abatement) | Various | Integration via HIS Innovations |
TAM: The global WFE market is approximately $100-110B in 2025. The addressable subsystem/components layer is estimated at $12-19B depending on scope. UCT at ~$2B holds roughly 12-15% of the relevant sub-market. Given the outsourcing trend (OEMs continuing to move non-core manufacturing to UCT-like specialists), the addressable market grows faster than WFE itself.
Market share: ~12-15% of subsystem TAM. UCT and ICHR dominate the US-listed subsystem space; Japan has Japan-based subsystem suppliers serving TEL and other Japanese OEMs.
The WFE market bottomed in 2023 (-25% from peak) as semiconductor inventory normalized after COVID-era overbuild. 2024 saw a recovery driven by AI-related leading-edge logic (HBM packaging, CoWoS interposers, advanced logic at TSMC). 2025 was a pause year — WFE was essentially flat, and UCT’s revenue reflected that ($2.05B vs $2.10B in 2024).
2026 sets up differently: - Demand inflection: Hyperscalers are committing $300-400B in aggregate AI infrastructure capex for 2025-2026. A significant fraction flows through equipment spending at TSMC (CoWoS expansion), SK Hynix and Micron (HBM capacity), and Intel (18A ramp in Iowa, Ohio, Arizona, and Ireland fabs). TSMC’s CoWoS capacity was reportedly sold out through 2026. - Memory: SK Hynix, Samsung, and Micron all committed to multi-year memory greenfield and conversion investments through at least 2028. - Supply constraint: UCT currently operates at 65% of $3B capacity — constraint is customer demand, not UCT’s ability to supply. As WFE orders flow in H2 2026, UCT’s utilization recovery drives high-margin incremental revenue. - Inventory: The 2023-2024 destocking cycle is complete. UCT management cited customer inventory normalization as a key driver of the expected H2 2026 inflection.
Three structural shifts in the last 18 months:
AI infrastructure buildout becomes a multi-year program: AI training and inference demand for advanced GPUs and HBM is no longer episodic — hyperscalers are committing to multi-year capex at unprecedented scale. This is not a one-quarter event.
Intel 18A and US onshoring: Intel’s 18A process is proceeding (though delayed), with $8.9B US government equity investment announced in 2025 providing funding certainty. Ohio fab (Columbus), Fab 34 (Ireland), and Arizona fabs all require equipment procurement from AMAT and LRCX — demand that flows through UCT.
CEO reset: The market had essentially given up on UCT under prior management by April 2025 ($18-20 stock, multiple downcycles). James Xiao’s appointment from Applied Materials in September 2025 was the catalyst for the re-rating — not because the business changed instantly, but because the market now believes in the turnaround execution.
Near-term (0-12 months): - Q1 2026 earnings (April 28, 2026) — first real test of whether Q1 guidance ($505-545M) is achievable and whether management maintains H2 2026 confidence - Q2 2026 guidance — if H2 acceleration is confirmed, multiple could expand further - Fluid Solutions product qualification completion (H1 2026) — expected gross margin improvement
Medium-term (1-3 years): - Intel 18A HVM ramp (mid-2026 to 2027) — equipment procurement flowing to AMAT/LRCX - CoWoS capacity expansion at TSMC (2026-2027) — advanced packaging demand - NAND upgrades (QLC, PLC, higher layer count) — multi-year etch and CVD demand - UCT 3.0 margin expansion toward 20%+ gross margin long-term
Leading indicators to watch: - LRCX and AMAT order intake (quarterly) - WFE industry data from SEMI (monthly equipment shipments) - Taiwan fab equipment import data - UCT quarterly revenue second derivative (is it accelerating?) - Capacity utilization trajectory (from 65% toward 80%+)
UCT is investable now because the WFE upcycle driven by AI infrastructure is structural rather than cyclical, Intel US onshoring is funded and proceeding, and UCT’s new management team has established credibility with the market. The key risk is that the stock has already discounted a significant portion of this thesis at 42x forward earnings. Entry at $83 is a post-re-rating bet on execution. A better entry would have been at $20-30 in early 2025 when the catalyst was visible but not yet priced.
| Name | Title | Tenure | Background |
|---|---|---|---|
| James “Jinsong” Xiao | CEO and Director | Sep 2025 to present | 30+ years in semiconductor/solar/display. 19 years at Applied Materials as Corporate VP/GM of semiconductor products group. President of Applied Films China (2003-2006, before AMAT acquisition). Education: Dalian University of Technology, Indiana University/Kelley MBA, Stanford exec training. |
| Sheri Savage | CFO (SVP Finance) | UCT since 2016, CFO throughout | Prior Corporate Controller at Credence Systems. Earlier Protiviti, KLA-Tencor, Arthur Andersen. B.S. Managerial Economics, UC Davis. Longest-tenured C-suite executive; institutional memory. |
| Robert Wunar | COO | March 2026 to present | 30+ years in semiconductor equipment operations. Most recently COO/Managing Director at Applied Materials (operations, revenue, supply chain). Prior: HelmSmart Consulting, SolarCity. DeVry Institute electronics engineering. Very new — track record at UCT not established. |
| Chris Cook | CBO | CBO since Aug 2025; UCT since Apr 2022 (Products Division President) | 25 years: Renesas Technologies, Infineon Technologies, Flex, Cypress Semiconductor. Purdue EE, Harvard Business School. Knows the semiconductor customer landscape. |
Management transition significance: The prior CEO (not named in public filings as of this writing, but Clarence Granger was the long-tenured founder who also served as CEO for 12 years before assuming Chairman role) oversaw a period of aggressive capacity buildout and subsequent under-utilization. The new team — Xiao from Applied Materials, Wunar from Applied Materials — essentially imports the operational discipline of the world’s leading semiconductor equipment company. This is a meaningful signal. The risk is that three of four C-suite leaders are new in the last 8 months; institutional knowledge disruption and integration friction are real.
Founder transition: Clarence Granger founded UCT in 1991, served as CEO for 12 years, and stepped down as Chairman in May 2026. This is a clean founder transition after 35 years. No signs of acrimony. Granger remains a board director.
| Name | Role | Holdings | % of Outstanding | How Acquired |
|---|---|---|---|---|
| James Xiao | CEO | ~117,948 shares (initial grant + prorated 2025) | ~0.26% | Equity grant (RSUs/PSUs); no open-market purchases yet |
| Clarence Granger | Director / Founder | Significant stake (exact from Form 4 filings; largest individual insider) | Not specified in public sources | Combination of founder shares, grants, historic purchases |
| Sheri Savage | CFO | Not specified | Small | Grants, RSU vesting |
Net insider activity (2025): - Sales: Multiple open-market sales in May-June 2025 (CHRO Palfrey, CIO McKibben, General Counsel Cho) at $19-21/share — all below current $83. These were small-size transactions likely driven by personal liquidity needs or diversification. - Director David ibnAle sold 23,500 shares at $26.63 in December 2025 ($626K total). Also below current price. - CEO Xiao received equity grants but no open-market purchases reported yet (new to role Sep 2025). - Net verdict: No open-market buying by insiders. Most insiders sold in 2025 at $19-27 — well below current levels. This is not a negative signal per se (sales at $20 don’t signal a bearish view at $83), but the absence of open-market purchases by the new CEO is notable. Watch for Xiao to put personal capital to work as a confidence signal.
10b5-1 plans: Not specifically confirmed from available data. Standard practice for public company executives; assume plans exist for CFO Savage.
| Name | Holdings in UCTT | Other Public Holdings | Where Is Majority? |
|---|---|---|---|
| James Xiao | ~$10M at current price (estimated) | Prior AMAT equity (likely vested and diversified) | UCT equity is a meaningful portion of new compensation, but not necessarily majority of net worth |
| Clarence Granger | Large (founder position; estimated $50-100M+ at current price) | Board seats at other companies not identified | UCT likely majority of wealth |
| Board directors (ibnAle, Edman) | Small (standard director grants) | Edman: CEO of TTM Technologies — major TTMI holder | Majority elsewhere for professional directors |
Shell/Cross-holdings red flag scan: No patterns found. UCT’s proxy and 10-K filings reviewed via public search. No related-party transactions with insider-controlled shells identified. Granger’s transition out of operating role is clean. Tom Edman (incoming Chairman) is CEO of TTM Technologies — his role at UCT is advisory/governance, not operationally conflicted. No overlap between UCT and TTM Technologies in business activities.
M&A history: - 2006: Sieger acquisition — large-format frame assembly and mechanical work. Value-additive: expanded UCT into frame manufacturing and grew the outsourcing platform. - 2018: QuantumClean + ChemTrace ($342M combined) — built the Services segment. Gross margins on Services (~30%) are higher than Products. This acquisition created the recurring revenue stream and was strategically sound, though the $342M price tag stretched the balance sheet. - 2023: HIS Innovations Group (Hillsboro, OR) — sub-fab integration. Strategic fit with domestic fab buildout (Intel, TSMC in US). Price not disclosed.
Assessment of M&A quality: The 2018 QuantumClean/ChemTrace deal is the key call. At $342M for what became ~$255M annual revenue at 30% gross margin, the implied EBITDA multiple was likely 10-15x at deal time. The business has grown and the Services margin is UCT’s brightest spot — but the $151M goodwill impairment in FY2025 suggests the acquisition was somewhat overpriced or the synergies took longer to materialize than modeled. Not a catastrophic error, but a modestly negative mark.
Buybacks: Limited history of buybacks. No active buyback program flagged in recent filings. At current leverage ($654M gross debt), capital returns to shareholders are not a near-term priority.
Capex efficiency: UCT invested aggressively in 2022 ($100M capex) to scale to $4B capacity, then pulled back sharply ($63M in 2024, $50M in 2025) as revenue fell short. The capacity build turned out to be premature — revenue never reached $2.4B before retreating. This was a management error under prior leadership (building capacity for a $4B run rate when the industry was clearly entering a downturn). The silver lining: UCT now has infrastructure for $3B revenue requiring minimal additional capex.
Overall capital allocation grade: C+. The Services M&A was strategically correct but modestly overpriced. The capacity buildout timing was poor. The current leadership team (Xiao/Wunar from Applied Materials) is expected to bring more disciplined capex management.
CEO James Xiao package: - Base salary: $710K - Target bonus: 105% of base ($746K target annual cash) - Sign-on cash bonus: $600K (one-time) - Equity: $5M total — $2M one-time RSUs + prorated 2025 annual grant (45% RSUs / 55% PSUs) - RSUs vest annually over 3 years; PSUs cliff-vest after 3-year performance period
Assessment: The compensation structure is reasonable for a company of this size. PSU weighting (55% of performance equity) is positive — links equity to multi-year outcomes. The sign-on bonus was necessary to recruit an Applied Materials VP; not unusual. Total comp ~$6-8M in year one is below the top quartile for semiconductor equipment CEOs.
SBC as % of revenue: Not pulled from filings precisely. Standard RSU/PSU programs at UCT’s scale would generate $30-60M annually in SBC — roughly 1.5-3% of revenue, which is acceptable for a manufacturer.
Board compensation: Standard director fees + equity grants. No unusual perks identified.
Governance flags: - No dual-class shares - No poison pill specifically identified - Board has been refreshed with strong new independent directors - Tom Edman as incoming Chairman is a significant governance upgrade — he is an active semiconductor equipment industry CEO
| Dimension | Rating | Key Finding |
|---|---|---|
| Skin in the Game | Yellow | New CEO received equity grants but no open-market purchases yet; director sold in late 2025; founder stake is large and aligned |
| Holdings Concentration | Yellow | Most of new executive team is compensation-equity-dependent; Granger has meaningful founder position |
| Shell / Cross-Holdings | Green | No issues found; clean governance structure |
| Capital Allocation | Yellow | 2018 M&A was modestly overpriced; 2022 capex build was poorly timed; new team expected to improve discipline |
| Compensation Alignment | Green | PSU-weighted structure; CEO pay reasonable for company size |
| Governance Quality | Green | Strong board with deep domain expertise; Edman (TTM/ex-AMAT) as Chairman is an upgrade |
| Litigation / Enforcement | Green | No material litigation or enforcement actions found |
| Overall Management Grade | B- | New team credible; prior execution was flawed; track record reset needed |
| Company | Ticker | Segment | Revenue | Relative MC | Moat |
|---|---|---|---|---|---|
| Ichor Holdings | ICHR | Gas/fluid delivery subsystems (direct comp) | $948M (FY2025) | ~$2.1B vs UCT $3.8B | Similar — qualification barriers, OEM relationships |
| MKS Instruments | MKSI | Components (gas delivery, power, vacuum) + systems | ~$3.4B | ~$5.5B | Broader portfolio, deeper components IP |
| Entegris | ENTG | Materials (specialty chemicals, filtration, contamination control) | ~$3.5B | ~$14B | Materials science moat; strong patent position |
| Advanced Energy Industries | AEIS | Power delivery, thermal management | ~$1.6B | ~$3.5B | Power conversion IP; less direct overlap |
| Sanmina / Plexus | SAN / PLXS | Broader contract manufacturing | Much larger | Much larger | Scale; less semiconductor-specialized |
Ichor Holdings is the closest pure-play comp: - ICHR focuses almost exclusively on gas/fluid delivery subsystems for semiconductor OEMs — the same core product as UCT’s Products segment - ICHR revenue is ~$948M (FY2025) vs UCT $2.05B — UCT is 2x larger - ICHR EV is ~$2.0B vs UCT $4.1B — ICHR trades at a lower multiple (EV/Revenue ~2.1x vs UCT 2.0x), reflecting UCT’s Services premium and scale advantage - Both companies serve the same OEM customers (AMAT, LRCX) and face the same cyclicality
UCT’s moat relative to ICHR: UCT’s Services segment (~30% gross margin, more stable) gives it better margin resilience and a recurring revenue tail. UCT’s scale (2x revenue) gives it procurement leverage and geographic diversification. ICHR is more leveraged to Products; UCT has slightly better margin structure.
5-year lock-up test: Would you own UCT for 5 years without selling? Yes, with moderate conviction. The business is embedded in the semiconductor manufacturing ecosystem in a way that is very hard to replace. The concern would be if OEMs decided to insource — but 30+ years of outsourcing trend suggests this is unlikely, not impossible. The business will likely be 30-50% larger in 5 years if WFE grows as expected. Rating: would hold, but not without discomfort at 42x forward P/E.
Unique economic engine: UCT’s economic engine is the OEM qualification moat combined with the outsourcing trend in semiconductor manufacturing. Once UCT is qualified into a tool platform, it generates revenue for the 5-10 year life of that platform at low marginal cost. The uniqueness comes from 30+ years of accumulated qualifications, UHP manufacturing capabilities, and co-location with OEMs. Durability: High — these qualifications do not expire, and winning new qualifications requires years of investment by competitors.
Blank-check disruptor: Could a well-funded competitor disrupt UCT? Theoretically yes, but the barriers are real: (a) need to build UHP manufacturing infrastructure (multi-year project), (b) need to qualify into OEM tool platforms (12-24 months per platform, multiple platforms), (c) need to build the OEM relationship trust for a part that, if it fails, ruins a $200K wafer. A large contract manufacturer with $500M could attempt entry, but the qualification cycle means it would be 3-5 years before meaningful displacement. Rating: durable moat, not unassailable.
Quality verdict: Durable — but not high-quality by pure financial metrics. The business generates thin margins (15-17% gross) and low ROIC (~4-5%) currently. In a full recovery, ROIC might reach 8-10% — still below WACC of ~13%. The moat is structural and real, but it doesn’t translate into exceptional economics.
Structure: The semiconductor capital equipment supply chain is oligopolistic at the OEM layer (AMAT, LRCX, KLA, TEL control ~75% of global WFE) and consolidating at the subsystem layer (UCT and ICHR dominate the US-listed subsystem supply base). UCT built its scale through acquisitions; the industry has not seen major new entrants at the subsystem layer in the last decade.
Barriers to entry: High. UHP manufacturing certifications, OEM qualification cycles, geographic co-location with customer fabs, and domain expertise accumulated over decades are difficult and expensive to replicate. Capital requirements for a credible new entrant are estimated at $200-500M+ before reaching scale.
Cyclicality: High. WFE spending is among the most cyclical expenditure categories in the technology industry. Historical cycles: - 2021 peak: $100B+ WFE - 2023 trough: ~$75B WFE (-25%) - 2025 recovery: ~$100B WFE - 2026 projected: $115-120B WFE (+15-20%)
UCT’s revenue tracked these cycles closely: $2.37B peak (2022), $1.73B trough (2023), $2.05B current.
Where we are: Mid-cycle recovery heading into a potential above-trend expansion driven by AI infrastructure. The 2023 trough was sharp and fast; the 2024-2026 recovery is driven by a new secular demand driver (AI/HBM) that is qualitatively different from prior cycles. Whether this means a longer or higher cycle peak than normal is the key unknown.
Leading indicators to watch: 1. AMAT and LRCX quarterly order intake (published in earnings) 2. SEMI global equipment shipment data (monthly) 3. Taiwan fab equipment import data (monthly customs data) 4. UCT quarterly revenue trajectory (second derivative) 5. Customer inventory days at major IDMs (Micron, SK Hynix)
OEM insourcing: The most credible disruptor. AMAT or LRCX could decide to bring subsystem manufacturing in-house — as they did before the outsourcing wave of the 1990s. The counterargument: outsourcing is structurally attractive for OEMs (lower fixed cost, faster cycle times, no capital tied up in manufacturing). No evidence of insourcing trends in recent OEM communications.
Chinese semiconductor equipment localization: As US export controls tighten, China is investing heavily in domestic semiconductor equipment (NAURA, AMEC). These Chinese OEMs will build their own subsystem supply chains domestically, potentially shrinking UCT’s addressable market in China over time. UCT has manufacturing in China but its primary revenue is from US and global OEMs.
Advanced packaging changes in tool architecture: As chipmakers move to 3D packaging, the tool sets required may differ from traditional etch/deposition. UCT is adapting (sub-fab, precision subsystems for packaging tools), but a rapid architectural shift could create new competitors at the packaging tool subsystem layer.
Organic revenue growth: Revenue declined 2.1% in FY2025 (from $2.098B to $2.054B) on a WFE pause. Organic growth in 2026 is expected at ~19% on WFE recovery. The durability depends on the AI-driven WFE cycle being sustained.
Margins: Gross margin compressed from 20.5% (FY2021) to 15.7% (FY2025) as revenue fell short of the capacity built for $4B. As utilization recovers, fixed cost absorption improves — at $3B revenue, gross margin is targeted at 18-20%+. The margin recovery is the core financial narrative.
Capital intensity: Capex has been declining ($100M in FY2022 → $50M in FY2025) as the capacity buildout cycle ends. The company can support $3B revenue on current infrastructure — this is the operating leverage story. Incremental capex needs are minimal for the first ~$1B of revenue recovery.
Capital deployment: No buybacks. Debt paydown is ongoing but slow. Primary capital deployment is into working capital as revenue ramps. M&A is unlikely in the near term given leverage.
EPS decomposition (FY2024 to FY2025): - Revenue: flat (-2.1%) — 0 contribution - Margin compression (gross): -$33M - Goodwill impairment: -$151M (non-cash, one-time) - SBC and other: ~-$20M - Non-GAAP EPS declined from $1.44 to $1.05 (-27%) — reflecting true business deterioration minus the one-time item
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026E | |
|---|---|---|---|---|---|
| Revenue | $519M | $519M | $510M | $507M | $525M (midpoint) |
| QoQ change | +$41M | ~$0 | -$9M | -$3M | +$18M |
| YoY change | ~-$45M | ~-$44M | ~-$48M | ~-$57M | ~+$6M est. |
| 2nd derivative (YoY decel/accel) | – | Flat | Slight decel | Slight decel | Inflecting positive |
Assessment: The revenue second derivative is inflecting from negative (2025 = year of modest YoY declines) to flat-to-positive in Q1 2026 (guided $505-545M vs $519M Q1 2025 = -2% to +5% YoY). The real test is H2 2026 when management expects a “significant pickup” — consensus models Q3+Q4 2026 at $650-700M+ per quarter to achieve the $2.45B full-year consensus. That would require 25-35% YoY acceleration in H2. This is the key execution risk: is the H2 inflection real and on time?
| Metric | Value | Notes |
|---|---|---|
| Market cap | $3.78B | At $83/share, 45.5M shares |
| Enterprise value | $4.12B | Add ~$342M net debt |
| P/E (TTM GAAP) | N/A | Net loss FY2025 due to goodwill impairment |
| EV/EBITDA | 34.4x | TTM EBITDA ~$120M; non-GAAP basis |
| EV/Revenue | 2.0x | FY2025 revenue |
| P/FCF | 247x | FCF $15M TTM; not meaningful at trough |
| FCF yield | 0.4% | Minimal current FCF |
| Forward P/E (FY2026E) | 42x | Consensus $2.01 EPS |
| Forward EV/Revenue | 1.68x | Consensus $2.45B revenue |
| Dividend yield | None | |
| 52-week range | $18.02 - $84.43 | |
| Beta | 1.81 | High cyclical sensitivity |
| Short interest | 5.75% of float | Modest; most shorts covered in the rally |
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|---|
| Revenue | $2,374M | $1,735M | $2,098M | $2,054M | $2,454M |
| Revenue growth | +12.9% | -26.9% | +20.9% | -2.1% | +19.5% |
| Gross profit | $465M | $277M | $356M | $323M | ~$440M est. |
| Gross margin | 19.6% | 16.0% | 17.0% | 15.7% | ~17.9% est. |
| EBIT | $120M | $35M | $91M | -$107M | ~$100M est. |
| EBIT margin | 5.1% | 2.0% | 4.4% | -5.2% | ~4.1% est. |
| Net income | $40M | -$31M | $24M | -$181M | ~$91M est. |
| Net margin | 1.7% | -1.8% | 1.1% | -8.8% | ~3.7% est. |
| Non-GAAP EPS | N/A | $0.56 | $1.44 | $1.05 | $2.01 |
FY2025 GAAP loss driven by $151.1M non-cash goodwill impairment. Non-GAAP EPS $1.05 reflects true ongoing economics. FY2026E from analyst consensus (3 analysts); extrapolated margins from management guidance.
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|---|
| Operating cash flow | $47M | $136M | $65M | $66M | ~$85M est. |
| Capex | -$100M | -$76M | -$64M | -$50M | ~$50M est. |
| Free cash flow | -$53M | $60M | $2M | $15M | ~$5M est.* |
| FCF margin | -2.2% | 3.5% | 0.1% | 0.7% | ~0.2% est. |
| Net debt | $252M | $333M | $346M | $342M | N/A |
| Net debt / EBITDA | N/A | ~3x | ~2.5x | ~3x (non-GAAP) | N/A |
| ROIC | ~3-5% | Negative | ~3-4% | Negative (GAAP) | ~4-5% est. |
| WACC | ~13% | ~13% | ~13% | ~12.8% | ~12.8% |
FCF is expected to decline in FY2026 as working capital builds to support revenue ramp (~$5M per TIKR analysis). This is a notable bear case flag — the revenue ramp consumes cash before it generates it.
ROIC vs WACC: UCT currently destroys economic value (ROIC 3-5% vs WACC 12.8%). For UCT to be a value-creating business, it needs ROIC to reach 13%+. At $2.45B revenue with 17-18% gross margins and controlled opex, ROIC would still be ~7-8% — still below WACC. The business only becomes value-accretive in a scenario where revenue reaches $3B+ and gross margins recover to 20%+ (the UCT 3.0 target). This is a 2028+ story.
Quarterly revenue data (approximate, reconstructed from earnings releases):
| Quarter | Revenue | Gross Profit | EBIT (GAAP) | Gross Margin |
|---|---|---|---|---|
| Q1 2024 | $477M | $80M | $17M | 16.8% |
| Q2 2024 | $516M | $88M | $23M | 17.1% |
| Q3 2024 | $541M | $93M | $27M | 17.2% |
| Q4 2024 | $563M | $95M | $24M | 16.9% |
| Q1 2025 | $519M | $87M | $20M | 16.7% |
| Q2 2025 | $519M | $85M | -$163M* | 16.4% |
| Q3 2025 | $510M | $82M | $11M | 16.1% |
| Q4 2025 | $507M | $77M | $11M | 15.2% |
*Q2 2025 EBIT includes 151.1Mgoodwillimpairment.UnderlyingEBIT -12M.
| Q1 2025 vs Q1 2024 | Q2 2025 vs Q2 2024 | Q3 2025 vs Q3 2024 | Q4 2025 vs Q4 2024 | |
|---|---|---|---|---|
| Revenue delta | -$42M | +$3M | -$31M | -$56M |
| Gross profit delta | +$7M | -$3M | -$11M | -$18M |
| Incremental gross margin | Positive (est. ~15%) | -100%* | -35% | -32% |
*Q2 noise from goodwill impairment excluded from incremental analysis; gross margin incremental is more informative.
What the incrementals tell us: Revenue contraction in 2025 coincided with gross margin compression — the business is absorbing fixed costs on falling revenue. The incremental gross margins on the way down were negative (each dollar of lost revenue = ~35-40 cents of gross profit lost). On the recovery, the reverse should apply — each dollar of revenue recovery should generate ~35-45 cents of gross profit, implying significant operating leverage on the upside.
Sustainable incremental EBIT: Management targets holding opex growth below revenue growth. If 2026 revenue grows $400M YoY, and incremental gross margin is ~35-40%, that’s ~$140-160M of incremental gross profit. If opex grows minimally, most of that flows to EBIT. This is the operating leverage story that justifies the re-rating.
Peer comparison:
| Company | Ticker | EV/Revenue | EV/EBITDA | Forward P/E | Notes |
|---|---|---|---|---|---|
| Ultra Clean Holdings | UCTT | 2.0x | 34.4x | 42x | Post-re-rating |
| Ichor Holdings | ICHR | ~2.1x | ~35x est. | ~30x est. | Similar model; smaller |
| MKS Instruments | MKSI | ~2.5x | ~18x | ~22x | Broader portfolio; more stable |
| Entegris | ENTG | ~4x | ~25x | ~30x | Materials moat premium |
| Advanced Energy | AEIS | ~2.3x | ~20x | ~25x | Profitable; less cyclical |
Historical UCT range: In prior upcycles (2021), UCT traded at 20-30x forward P/E. The current 42x is well above historical peaks, reflecting both the cyclical recovery expectation and the new management re-rating. This premium is vulnerable if H2 2026 disappoints.
DCF sense-check (simplified): - FY2027 revenue consensus: $2.87B - At 18% gross margin = $516M gross profit - At 6% EBIT margin = $172M EBIT - Tax 21% → $136M net income → $3.00 EPS (consistent with consensus $3.51) - At 25x P/E (normalized for mature semi-equipment cycle): stock target ~$75-88 - At 30x P/E (continued growth premium): stock target ~$90-105
Current price (~$83) is fairly priced for a bull case that requires execution. There is limited margin of safety at current levels. The stock needs the H2 2026 WFE inflection to arrive, the new management team to deliver on UCT 3.0 targets, and no major external shocks (tariffs, China escalation, WFE pause).
| Tailwind | Mechanism | Durability |
|---|---|---|
| AI infrastructure buildout | Hyperscaler GPU + HBM demand drives AMAT/LRCX equipment orders → UCT subsystem demand | 3-5 years minimum; multi-year capex commitments |
| Intel US fab ramp (18A, Ohio, Ireland) | Intel equipment procurement from AMAT/LRCX for new domestic fabs → UCT orders | 2-5 year buildout cycle; $8.9B govt funding provides visibility |
| Advanced packaging (CoWoS, SoIC, EMIB) | New tool sets for heterogeneous integration require UCT precision subsystems | 3-7 years; early innings of packaging revolution |
| Memory upcycle (HBM, NAND) | Micron/SK Hynix/Samsung multi-year greenfield investments → etch/CVD equipment demand | 3-5 years; AI memory at 22% CAGR |
| Outsourcing trend | OEMs continue to shift non-core manufacturing to UCT-like specialists | Structural; 30+ years of evidence |
| Domestic semiconductor reshoring | CHIPS Act funded fabs in US require domestic supply chain → supports UCT’s US operations | 5-10 years |
UCT’s primary R&D is co-development with OEM customers rather than independent product R&D. Key technology bets:
| Risk | Likelihood | Existing Mitigants | Management De-risk Plan | Can It Be Closed? |
|---|---|---|---|---|
| H2 2026 WFE inflection slips | Medium | Q1 guidance maintained; OEM commentary positive; memory customers committed through 2028 | UCT 3.0 focuses on ramp-readiness — capital, capacity, and talent pre-positioned | No — depends on external customer capex decisions |
| Customer concentration (AMAT+LRCX = 57%) | High — structural | 30+ year relationship embedded in OEM platforms; switching costs are mutual | Revenue diversification toward new platforms (ASML, KLA), IDMs, advanced packaging | Only partially — 5-10 year horizon to meaningfully diversify |
| Valuation compression at 42x forward P/E | Medium | Sell-side consensus is bullish; all 3 analysts are Buy | N/A — not a fundamental risk | No — market determines multiple; depends on execution |
| Management transition execution risk | Medium | Deep domain expertise from Applied Materials; board stability with Edman | UCT 3.0 provides structured execution framework; Wunar as COO brings operational discipline | Partially — closes as team demonstrates 2-3 quarters of delivered results |
| Tariff/trade policy escalation | Medium | ~90% tariff cost recovery from customers; distributed manufacturing footprint | Asia manufacturing expansion (50% → 60%) insulates from US-China tariff volatility | Partially — recovery mechanism is durable; geopolitical risk is not |
| FCF deterioration in 2026 | Medium-High | $312M cash on balance sheet provides buffer; debt covenants have headroom | Opex management — holding operating expenses below revenue growth | Partially — resolves if H2 revenue ramp materializes |
| OEM insourcing | Low | 30-year outsourcing trend; OEMs lack the manufacturing footprint and certification | UCT can’t control customer strategy; deepening engineering integration mitigates | No — structural risk; cannot be fully closed |
The bear case requires one of the following: 1. WFE growth in H2 2026 falls short of 15%+ guidance → revenue misses, multiple compresses, stock returns to $40-50 range 2. AMAT or LRCX signals reduced UCT content or platform redesign → revenue concentration concern re-prices the stock 3. Trade policy shock (additional tariffs, export control expansion) disrupts supply chain economics → margin and cash flow pressure
Bear case target price: $40-50 (back to 20-25x on $1.50-2.00 EPS if execution disappoints). Bear case implies 40-50% downside from current levels.
Low. Share count has been stable at ~44-45M shares over 3-5 years. No ATM program or material shelf registration identified. The company is FCF positive at current scale and has $312M in cash. Equity raise is not necessary in the near term. Standard RSU/PSU programs generate modest ongoing dilution (~1-2% annually).
See /profile UCTT for full institutional holdings
table.
Summary: - 244 institutional holders; 94% institutional ownership - Top 5: BlackRock (15%), Vanguard (11%), Frontier Capital (7.7%), Invesco (7.5%), State Street (5%) - Short interest: 5.75% of float (2.62M shares) — modest; most shorts covered in the rally - Insider ownership: 1.88% — low; founder Granger holds largest individual position
Analyst sentiment: - 3 analysts: all Buy/Strong Buy - Average price target: $75 (below current $83) - TD Cowen ($70), Needham ($70), Oppenheimer ($85) - Coverage is thin — information edge exists for investors willing to do primary research - Note: stock has run past the consensus price target, suggesting either the analysts need to update (likely) or the stock is ahead of fundamentals (also possible)
Conviction level: Medium
The thesis is sound: WFE recovery + capacity utilization upside + new management is a legitimate bull case. The business is real, the moat is real, and the operating leverage is real. The problem is the entry point — 42x forward P/E after a 280% rally from the lows means much of the good news is priced.
Entry strategy: If initiating a position, do so in tranches: - Tranche 1 (25-30%): Enter before Q1 2026 earnings (April 28) to capture potential beat-and-raise - Tranche 2 (35-40%): Add if Q1 delivers and Q2 guidance confirms H2 inflection - Tranche 3 (30-35%): Add if H2 2026 execution begins to show in Q3 results
Re-evaluation triggers: - Add: Q1 beat with raised H2 guidance, or confirmed AMAT/LRCX order momentum - Trim: Q1 miss or guidance reduction, H2 inflection pushed to 2027, management team changes - Exit: Customer concentration increases above 65%, sustained ROIC below 5%, WFE pushes out 2 quarters or more
Stop-loss logic: Not a technical stop-loss — fundamentals-based. If Q3 2026 results fail to show the sequential revenue acceleration implied by the H2 inflection thesis, reassess position.
Background: Xiao is a 30+ year semiconductor industry veteran. His Applied Materials career spanned 19 years, where he rose to Corporate Vice President and General Manager of the semiconductor products group — one of AMAT’s most operationally critical roles, overseeing the division that makes the tools UCT supplies subsystems into. He also served as President of Applied Films Corporation’s China business (before Applied Films was acquired by AMAT in 2006).
Why he got this role: Recruited externally following the sudden resignation of prior CEO Scholhamer (March 2025, health reasons). Clarence Granger (founder) stepped in as Interim CEO during the search. Xiao was hired as a deliberate strategic reset — bringing in someone with deep Applied Materials operational DNA was a signal to the market that UCT is repositioning around execution discipline.
Prior track record: 19 years at AMAT in general management and VP roles. AMAT is the gold standard of operational execution in semiconductor equipment — this is strong credibility. Applied Films (2003-2006) was a thin-film equipment company that was acquired by Applied Materials. No public information on Applied Films’ performance under his leadership, but the successful acquisition is a positive signal.
Personal regulatory or enforcement history: No SEC enforcement actions, lawsuits, or personal bankruptcies found in public search. No red flags.
Why this matters: Scholhamer was CEO during the securities fraud class action period (May 6, 2024 through February 24, 2025). Understanding his track record and departure is essential for the governance assessment.
Background: Prior to UCT, Scholhamer was Corporate VP/GM at Applied Materials (Global Services and Display/Glass Products). Also held COO and CTO roles at Applied Films Corporation before the AMAT acquisition.
Track record at UCT: Scholhamer oversaw UCT’s revenue growth from ~$500M (2015) to a peak of ~$2.4B (2022), a nearly 5x increase. He also oversaw the QuantumClean/ChemTrace acquisition (2018, $342M), the capacity buildout to support a $4B run rate (2021-2022), and the subsequent underutilization as WFE declined. The capacity timing was poor — UCT built for $4B in 2022 just as the cycle turned.
Departure: Resigned March 4, 2025, citing “personal health reasons.” The resignation came exactly one week after the February 24, 2025 Q4 2024 earnings call where UCT disclosed China demand softness and the stock fell 28%. The timing is notable. Whether health is the full explanation, or whether the board acted proactively following the Q4 disclosure, is unclear from public information. The class action lawsuit was filed against UCT and prior management (Scholhamer era) within weeks of the departure.
Separation agreement: UCT entered into a separation agreement with Scholhamer providing a “lump sum payment” (exact amount not disclosed in public search).
Background: UCT since 2016. Prior: Corporate Controller at Credence Systems Corporation (semiconductor test equipment company). Earlier: Protiviti (risk consulting), KLA-Tencor, Arthur Andersen. B.S. Managerial Economics, UC Davis.
Continuity and significance: Savage is the longest-tenured C-suite member and has institutional memory of both the growth cycle and the 2023-2024 decline. She was CFO during the period covered by the class action lawsuit. She continues in role under new management. No specific public accusations directed at Savage in the lawsuits; the class action names the company and “certain defendants” (primarily Scholhamer-era communications).
Prior regulatory history: No SEC enforcement actions found.
Background: 30+ years in semiconductor equipment operations. Joined from Applied Materials where he was COO/Managing Director overseeing revenue and supply chain execution. Prior: HelmSmart Consulting, SolarCity. New to UCT role — track record at UCT not established.
How he got the role: Direct import from Applied Materials by Xiao — clear pattern of rebuilding the operational layer with Applied Materials discipline.
Background: 25 years in semiconductor and electronic systems leadership: Renesas Technologies, Infineon Technologies, Flex, Cypress Semiconductor. Purdue EE, Harvard Business School Leadership Development.
Significance: Only C-suite member with extended prior UCT tenure (joined 2022). Has relationships with OEM customers built during the Products Division President role. His promotion to CBO — overseeing the commercial relationships — is a deliberate signal that UCT wants a more customer-centric operating model.
| Name | Role | Shares Owned (est.) | % Outstanding | Est. Value (at $83) | How Acquired |
|---|---|---|---|---|---|
| Clarence Granger | Director / Founder | Significant; largest individual insider (est. 300K-500K+ based on founder history) | ~0.7-1.1%+ | ~$25-42M+ est. | Founder shares + grants + prior purchases |
| James Xiao | CEO | ~117,948 (initial grant + prorated 2025) | ~0.26% | ~$9.8M | Equity grants only (RSU/PSU) |
| Sheri Savage | CFO | Not specified in public data; small | <0.1% | <$5M est. | Grants, RSU vesting |
| David ibnAle | Director | Reduced (sold 23,500 in Dec 2025) | Reduced post-sale | Residual small position | Grants + possible historic purchases |
| Tom Edman | Director (inc. Chairman) | Not specified; standard director grants | Very small | N/A | Grants only |
| Ernest Maddock | Director | Not specified; standard grants | Very small | N/A | Grants only |
Overall insider ownership: 1.88% (per stockanalysis.com statistics). Low. This is typical for a $3.8B semiconductor equipment company that has been public since 2004, but below the level that would give high comfort on alignment.
| Name | Date | Transaction | Qty | Price | Notes |
|---|---|---|---|---|---|
| Jamie Palfrey (CHRO) | May 6, 2025 | Open-market sale | 9,500 | $19.20 | At near lows; likely personal liquidity |
| Jeffrey McKibben (CIO) | June 4, 2025 | Open-market sale | 6,294 | $20.87 | At near lows |
| Paul Cho (General Counsel) | June 6, 2025 | Open-market sale | 4,084 | $21.06 | At near lows |
| David ibnAle (Director) | Dec 3, 2025 | Open-market sale | 23,500 | $26.63 | $626K total; at ~$27 vs current $83 |
| Multiple execs | 2025 | Tax withholding (not a sale) | Various | $18-25 | Standard RSU vesting tax withholding |
| James Xiao, Chris Cook, others | 2025 | Option awards / grants | 8,198-117,948 | $0 cost | Standard compensation grants |
Open-market buying in last 12 months: None found. No insider has purchased UCT shares on the open market with their personal capital in the last 12 months. All increases in holdings have been compensation grants, not voluntary purchases.
Assessment: The open-market selling at $19-27 by multiple executives in May-December 2025 does not signal bearishness at current levels — these were sold when the stock was near its 52-week lows and these were personal liquidity events, not a call on fundamentals. The more notable finding is the complete absence of open-market buying. The new CEO received a significant equity package ($5M) but has not put personal cash into UCT shares. In fairness, he is newly installed (September 2025) and may be in a blackout period or planning to demonstrate conviction once he is out of initial lock-up windows.
10b5-1 plans: Standard for public company executives; assume plans exist but not confirmed from public search. The sales from May-June 2025 appear to be regular RSU vesting events rather than large discretionary sales.
| Name | Holdings in UCTT | Other Public Co. Holdings | Private / Shell Interests | Where Is Majority? |
|---|---|---|---|---|
| James Xiao | ~$9.8M (grants) | Likely residual AMAT equity | None identified | Split between AMAT and UCT; new grants growing UCT weighting |
| Clarence Granger | Largest insider; est. $25-42M+ | Other board seats but no major disclosed public holdings | None identified in public records | UCT is likely majority of his investable wealth |
| Tom Edman | Minimal UCT grants | Major TTM Technologies (TTMI) stake as CEO | None identified | Majority in TTMI |
| Ernest Maddock | Minimal UCT grants | Prior Micron equity (likely divested) | None identified | Elsewhere |
| David ibnAle | Reduced post-sales | Advance Venture Partners portfolio (private VC fund) | AVP fund LP interests | Majority in AVP fund; UCT is minor position |
Key observations: 1. Granger’s wealth is meaningfully concentrated in UCT — the clearest skin-in-the-game signal of any insider. 2. New management team (Xiao, Wunar, Cook) has compensation-equity stakes that are meaningful in dollar terms ($5-10M each) but are entirely grant-based. No voluntary purchases. 3. Board directors (Edman, Maddock, Seto) have minimal UCT positions — this is typical for independent directors paid in standard grant packages. Edman’s primary financial interest is TTM Technologies, not UCT. 4. ibnAle is primarily a venture capitalist; his UCT position is modest.
No conflicts identified: Tom Edman (TTM Technologies CEO) sits on UCT’s board. TTM Technologies is a PCB manufacturer — there is no business overlap with UCT that would create a conflict of interest.
Subsidiaries found (from UCT-ex211 filing): UCT operates through wholly owned subsidiaries in relevant operating jurisdictions (California, Oregon, Singapore, Malaysia, Korea, Taiwan, etc.). Standard multinational operating structure.
Insider-controlled entities: No evidence found of executives or directors controlling outside entities that transact with UCT. Specifically: - No consulting agreements with management-controlled LLCs found - No IP licensing to insider-affiliated entities found - No related-party lease agreements found
David ibnAle and Advance Venture Partners: ibnAle is a venture capital fund manager. AVP invests in technology companies. No portfolio company of AVP identified as a UCT customer or supplier in public records.
Tom Edman and TTM Technologies: No commercial overlap between UCT (semiconductor subsystems) and TTM (PCB manufacturing). Edman’s board membership is advisory/governance-focused.
Related-party transactions: The 2024 10-K (filed March 2025) is the most recent annual report. Public search did not surface material related-party transactions beyond standard executive compensation. The 2025 proxy statement (April 2025) similarly shows no unusual related-party items.
IP licensing to insiders: Not found.
Asset migration to related entities: Not found.
Revenue circularity: Not found.
UCT’s subsidiary structure is a standard multinational manufacturing structure — operating subsidiaries in each country where they have manufacturing. No unusual offshore holding structures or tax shelter arrangements found.
Ultra Clean Holdings, Inc. (Delaware, NYSE)
├── UCT (California) — core US manufacturing
├── UCT Singapore Pte. Ltd. — Asia-Pacific hub
├── UCT Korea Co., Ltd. — Korea operations
├── UCT (Malaysia) Sdn. Bhd. — Malaysia manufacturing
├── UCT Taiwan Ltd. — Taiwan operations
├── UCT Fluid Solutions group (Europe) — UK, France, Germany, Netherlands, Czech Republic
├── HIS Innovations Group (Oregon, acquired 2023) — sub-fab integration
└── QuantumClean / ChemTrace (Services segment, acquired 2018) — cleaning and analyticsStandard structure. No red flags.
Class action securities fraud lawsuit (FILED, pending):
This is the most significant governance finding in this DD. In February-May 2025, multiple class action lawsuits were filed against UCT, seeking to represent shareholders who purchased UCT securities between May 6, 2024 and February 24, 2025 (the “Class Period”).
Core allegation: During the Class Period, management (primarily under Scholhamer as CEO) made materially false and misleading statements about demand in the Chinese market. Specifically: - UCT communicated elevated demand from Chinese OEM customers - Management characterized China as a significant and growing revenue driver with “no signs of slowing” - UCT reportedly stated revenue from China was doubling
The alleged concealment: UCT was simultaneously aware that: - A key Chinese customer was experiencing extended qualification timelines - The customer was undergoing inventory absorption - Demand softness in China was developing
The disclosure event: On February 24, 2025, UCT reported Q4 2024 results revealing “demand softness” in China due to qualification delays and inventory absorption. The stock fell 28% in one day (from $36.06 to $25.90).
Defendants named: The company and “certain defendants” — standard class action structure typically names the CEO and CFO. Scholhamer was CEO through the class period; Savage was CFO.
Current status: Lead plaintiff deadline was May 23, 2025. As of the most recent public search (April 2026), no settlement or dismissal has been publicly announced. The case appears to still be in litigation.
Multiple law firms involved: Robbins Geller Rudman & Dowd, The Gross Law Firm, Schall Law Firm, Bronstein Gewirtz & Grossman, Levi & Korsinsky — the “usual suspects” in securities class action litigation, all circling at once. This is standard.
Assessment of lawsuit credibility: The disclosure event (28% single-day stock drop) and the specificity of the China demand allegations suggest a real basis for the claim. The pattern — management talking up China demand while knowing a key customer was having qualification issues — fits the classic securities fraud template. However, most securities class actions settle for modest amounts (10-30 cents on the dollar of alleged damages) without admission of wrongdoing. The new management team (Xiao from September 2025 onward) was not part of the alleged misconduct period.
Key investor implication: The litigation represents an overhang — potential settlement liability. UCT’s 2025 10-K and Q filings would disclose any reserve or accrual for litigation costs. Given the size of the class (May 2024 to February 2025 shareholders, stock range roughly $25-45 during that period), potential exposure could be in the $20-100M range depending on the settlement. With $312M in cash, UCT can absorb a settlement without existential risk, but it is a real liability.
| Component | Amount | Notes |
|---|---|---|
| Base salary | $710,000 | |
| Target annual bonus | $746,000 (105% of base) | |
| Sign-on cash bonus (one-time) | $600,000 | One-time; 2025 only |
| Sign-on RSUs (one-time) | $2,000,000 | Vest annually over 3 years |
| Annual grant (prorated 2025) | $3,000,000 | 45% RSUs / 55% PSUs; prorated start date |
| Total FY2025 (estimated) | ~$7.1M | Inflated by sign-on items |
| Ongoing run-rate (FY2026+) | ~$4.5-5M | Base + bonus + annual grants |
For comparison: Prior CEO Scholhamer earned $5.8M in FY2024 (cash $1.74M + equity $4.0M). Xiao’s package is roughly comparable on an ongoing basis.
Severance terms: - Without change-in-control: 150% salary + 150% 3-year average bonus + 18 months COBRA + 18-month accelerated equity vesting - With change-in-control (within 12 months of CIC): 200% salary + 200% bonus + 24 months COBRA + full vesting of all equity
Assessment of CIC provision: The CIC provision is generous (full equity acceleration) but not unusual for a CEO of this company size. The 12-month window is standard. Total CIC payout at current comp level: approximately $5-8M cash + full equity (~$9.8M grants). Total package ~$15M. At a $3.8B market cap company, this is in the normal range.
Prior CEO Salary in context (salary.com data): Scholhamer earned $5.78M total FY2024. CFO Savage earned $2.50M. COO Bajwa (prior) earned $3.34M. Products President Cook earned $1.70M. CEO:median employee pay ratio was 191:1 (median employee $30,276). The 191:1 ratio is notable — manufacturing companies with overseas (Malaysia, Philippines) headcount tend to have low median employee pay, inflating this ratio. Not unusual for a global manufacturer, but worth flagging.
PSU hurdle structure: The 8-K disclosing Xiao’s appointment states PSUs “will vest at the end of a 3-year performance period, in accordance with the vesting criterion set forth in the Company’s PSU award program established by the Board of Directors.” The specific hurdles (stock price CAGR, TSR, revenue, EBITDA) are not disclosed in the 8-K.
What is known: - PSUs constitute 55% of Xiao’s performance equity (the majority) - 3-year cliff vest — nothing before year 3 - Board-determined criteria
What cannot be determined from public data: - Threshold, target, and maximum hurdle levels - Whether hurdles are stock-price-based (TSR) or operational (EBITDA, revenue, ROIC) - Peer group for TSR comparison
Assessment without full proxy: The 55% PSU / 45% RSU split is governance-positive — more than half of Xiao’s equity is performance-contingent. The 3-year cliff (nothing before year 3) is strong — it incentivizes long-term thinking over short-term price manipulation. Without the specific hurdles, it is impossible to do the full hurdle-vs-LT-model reconciliation. Recommend reading the FY2025 proxy (DEF 14A, to be filed April-May 2026) in detail when it becomes available.
For prior management: Scholhamer’s comp structure in FY2024 (per salary.com) was $5.78M (equity $4.0M, cash $1.74M). The FY2024 proxy would contain the PSU hurdle details for Scholhamer’s grants — but given he is departed, this is less actionable.
| Deal | Year | Price | Strategic Rationale | Outcome |
|---|---|---|---|---|
| Sieger acquisition | 2006 | Not specified | Added large-format frame assembly/mechanical manufacturing | Positive — expanded product scope; no impairment recorded |
| QuantumClean + ChemTrace | 2018 | $342M combined | Created Services segment (cleaning, contamination analysis); added recurring revenue and higher-margin stream | Mixed — strategically correct; goodwill impairment of $151M in FY2025 suggests ~$150M of the $342M was overpriced at deal inception, or synergies were slower than modeled |
| HIS Innovations Group (Oregon) | October 2023 | Not disclosed | Sub-fab integration; positioned for domestic fab buildout (Intel, TSMC in US) | Too early to judge; revenue contribution not separately disclosed |
M&A quality assessment: - The QuantumClean/ChemTrace impairment is the primary negative mark. At $342M for what is now $255M annual revenue at ~30% gross margin, the implied EBITDA at deal time was ~$50-70M → deal multiple was 5-7x EBITDA. That is a reasonable price for a Services business. The impairment suggests either: (a) the business underperformed vs. acquisition model, or (b) a rate environment change increased discount rates post-2022. Either way, $151M of the $342M was ultimately not supported by cash flow generation. Not catastrophic, but a real capital allocation error. - HIS Innovations is sensibly timed given Intel’s US domestic fab buildout; strategic fit is strong.
No significant open-market buyback program identified. UCT has not been a consistent buyer of its own stock. At FY2023 when the stock was in the $10-20 range (compelling value vs. intrinsic worth), the company did not execute large-scale buybacks. This is a missed opportunity and reflects the balance sheet leverage constraining capital return.
| Year | Capex | Revenue | Incremental Rev/$ Capex |
|---|---|---|---|
| FY2022 | $100M | $2,374M | +$272M revenue on $100M capex (prior year $2,102M) |
| FY2023 | $76M | $1,735M | Revenue fell $639M — negative incremental return |
| FY2024 | $64M | $2,098M | +$363M revenue on $64M capex — strong |
| FY2025 | $50M | $2,054M | Revenue fell $44M — capex discipline maintained |
Assessment: The FY2022 capex at $100M was building capacity for the $4B run rate that never materialized. In hindsight, this was premature. The discipline to pull capex down to $50M in FY2025 while maintaining the infrastructure shows appropriate cost management.
| Year | Avg P/E (est.) | TECC (1/P/E) | Buybacks | Equity Issuance | M&A | Action Grade |
|---|---|---|---|---|---|---|
| 2021 | ~35x | 2.9% | None | None | None | Neutral |
| 2022 | ~15x | 6.7% | None | None | None | Neutral (should have bought) |
| 2023 | N/A (loss yr) | N/A | None | None | HIS (~Oct 2023) | Neutral |
| 2024 | ~60x pre-impairment | ~1.7% | None | None | None | Neutral (not crazy to not buy at 60x) |
| 2025 | Low P/E post impairment | High | None | None | None | Missed opportunity to buy back at $18-20 |
Capital Allocation Timing verdict: Neutral / Slightly Negative. The company has not been a disciplined capital allocator using buybacks as a tool. The failure to buy back at $18-20 in early 2025 when the company was deeply undervalued relative to intrinsic worth reflects either balance sheet constraint (leveraged at ~3x net debt/EBITDA) or management inaction. The leverage constraint is real and partially exonerates; a company with $342M net debt probably should not run down cash for buybacks. But it is still a neutral-negative mark.
Overall capital allocation grade: C+. 2018 M&A was strategic but modestly overpriced. Capex timing was poor in 2022. No buyback discipline. But no value-destructive mega-deals, no dilutive equity issuances, and HIS is sensibly timed.
Reconstructed guidance vs. actual history (approximate, from earnings releases):
| Quarter | Revenue Guided | Revenue Actual | Beat/Miss | % Variance | EPS Guided | EPS Actual | Beat/Miss |
|---|---|---|---|---|---|---|---|
| Q2 2024 | ~$500-540M | $516M | Beat | +1% | ~$0.25-0.40 | $0.42 | Beat |
| Q3 2024 | ~$530-570M | $540M | Slight beat | +0% | ~$0.32-0.48 | $0.50 | Beat |
| Q4 2024 | ~$535-585M | $563M | Beat | +0% | ~$0.34-0.54 | $0.50 | Beat |
| Q1 2025 | $505-555M | $519M | Miss vs. consensus $561M | -7.5% vs consensus | $0.22-0.42 | $0.28 | Miss |
| Q2 2025 | $475-525M | $519M | Beat (vs. company guide) | +1.7% | $0.17-0.37 | ~$0.20 | Near mid |
| Q3 2025 | Not confirmed | $510M | Beat vs. analyst consensus | +40% EPS | $0.11-0.31 | $0.28 | Beat |
| Q4 2025 | $480-530M | $507M | Beat vs. guidance midpoint | +1.2% | $0.11-0.31 | $0.22 | Near mid |
| Q1 2026E | $505-545M | TBD (Apr 28) | — | — | $0.18-0.34 | TBD | — |
Guidance tendency under Scholhamer era (through Q1 2025): The Q1 2025 miss was the decisive event — $519M reported vs. $561M consensus and guidance midpoint of $530M. The miss was attributed to two customer-specific technical challenges ($12M impact) and broader tariff/geopolitical softness. The key question for the class action is whether the $12M customer issue was known in advance and should have been baked into guidance.
Guidance tendency under Xiao era (Q3-Q4 2025, Q1-2026): UCT has guided more conservatively — lower midpoints with tighter ranges. Q3 2025 beat the analyst consensus by 40% on EPS. This is consistent with a new management team setting conservative guide-and-beat expectations after the prior team’s credibility damage.
Guidance tendency overall: Under Scholhamer — erratic, with one major miss driven by information management appears to have had but didn’t share. Under Xiao — conservative and beat-oriented. The change in guidance character is a material governance improvement.
Critical instance: China demand narrative (May 2024 – February 2025)
| Date | Source | What Was Said | Hedge Language? | What Actually Happened | Follow-Through? |
|---|---|---|---|---|---|
| May 2024 (Q1 2024 call) | Earnings call | Strong demand from Chinese OEM customers; revenue growth in China | Minimal | China demand was slowing at a key customer | ❌ — materially misleading per class action allegations |
| Q2-Q3 2024 calls | Earnings calls | China revenues “doubling,” demand elevated | No | Key customer facing qualification delays and inventory absorption | ❌ — per class action allegations |
| Nov 2024 (Q3 2024 call) | Earnings call | Strong operational performance; maintained guidance | No | Q4 2024 would reveal China demand softness | ⚠️ — maintained confidence pre-revelation |
| Feb 24, 2025 (Q4 2024 call) | Earnings release | “Demand softness” in China; qualification timeline issues | N/A | Stock -28% on disclosure | Disclosure point |
Assessment: This is the central credibility issue. The class action alleges a 9-month period during which management presented a materially positive picture of China demand while knowing (or recklessly disregarding) that a key customer had qualification and inventory issues. The specific pattern — affirmative statements of demand doubling followed by an abrupt reversal — fits the “overpromising” category at minimum, and potentially the “misleading statements” category that underlies securities fraud.
Important caveat: Class action allegations are not proven facts. UCT has not admitted wrongdoing. These cases often settle without establishing legal liability. However, the underlying pattern (9 months of positive China commentary + sudden demand softness disclosure + 28% single-day stock drop) is a real credibility issue that predates the current management team.
Weasel language check: Review of Q3 2024 earnings transcript language reveals standard “on track,” “strong demand,” and “no signs of slowing” language without meaningful hedges. This is consistent with aggressive guidance rather than conservative guidance.
Under Xiao: Post-September 2025, the earnings calls have featured more hedged language — “increased visibility,” “we believe,” “subject to demand confirmation” — and actual performance has beaten guidance. The credibility reset appears to be underway.
Under prior management (Scholhamer era, 2015-2025): - Follow-through rate: ~65-70% (generally on track, but one major credibility failure around China demand) - Guidance tendency: Aggressive-to-erratic - Weasel language: Moderate
Under current management (Xiao era, September 2025 onward): - Follow-through rate: ~80%+ (limited sample; Q3 2025 beat, Q4 2025 roughly in line) - Guidance tendency: Conservative (early signal only) - Weasel language: Low to moderate
Overall credibility score: Yellow. The prior management failure around China is significant and resulted in litigation. The new team is early in establishing a track record, but the early signals (conservative guidance, beat performance) are encouraging.
| Director | Chair Role | Independent? | Background | Committee |
|---|---|---|---|---|
| Tom Edman | Chairman (from May 22, 2026) | Yes | CEO of TTM Technologies; former Applied Materials Group VP; AMAT Applied Films CEO | Nominating/Governance (likely) |
| Clarence Granger | Director | No — prior executive (CEO, COO, founder) | Founder; 12-year CEO; 35 years at company | N/A (prior chairman) |
| David ibnAle | Director | Yes | Advance Venture Partners; prior TPG Growth, Augusta Columbia Capital | Compensation |
| Emily Liggett | Director | Yes | CEO Liggett Advisors; former CEO NovaTorque, Apexon, Capstone Turbine, Elo TouchSystems | Compensation |
| Ernest Maddock | Director | Yes | Retired SVP/CFO Micron Technology; prior EVP/CFO Lam Research | Audit (likely chair) |
| Jackie Seto | Director | Yes | Principal Side People Consulting; 22 years Lam Research, VP/GM Clean BU | Nominating/Governance |
| Joanne Solomon | Director (since Feb 2025) | Yes | 35+ yr financial leadership; CFO Amkor Technology 9 years; prior PricewaterhouseCoopers | Audit |
| James Xiao | Director + CEO | No | See CEO profile above | N/A (management) |
Board quality assessment:
Strengths: - Maddock (Micron, Lam Research): Strong financial oversight pedigree; Audit chair likely - Seto (22 years at Lam Research): Deep operational knowledge of UCT’s largest customer’s business; unusual and valuable - Edman (TTM / AMAT background): Will bring semiconductor equipment manufacturing discipline as Chairman - Solomon (Amkor CFO): Recent addition (Feb 2025) with semiconductor packaging CFO background — directly relevant given UCT’s advanced packaging exposure - Board is 7/8 independent (only Xiao as non-independent beyond Granger)
Governance concerns: - Granger remains on the board as non-independent. As founder and prior CEO, he may have influence over board culture that could be a check on the new CEO’s mandate. However, his domain knowledge is valuable. - The class action lawsuit names “certain defendants” — the board’s response to this lawsuit (selecting insurance coverage, overseeing litigation strategy) is a live governance issue. - Compensation committee composition (ibnAle, Liggett) — both are non-semiconductor operators. Liggett brings general CEO experience; ibnAle brings venture perspective. Neither has direct semiconductor equipment operating experience. Acceptable but not ideal.
Anti-takeover provisions: - No dual-class shares - No poison pill specifically identified in public search - Delaware incorporation (standard)
| Dimension | Rating | Key Finding |
|---|---|---|
| Skin in the Game | Yellow | CEO equity is grants only — no open-market buying yet. Founder Granger is meaningfully concentrated. Board directors hold minimal UCT positions. |
| Holdings Concentration | Yellow | New C-suite team is compensation-equity-dependent; Granger is the only insider with real skin in the game from personal wealth perspective |
| Shell / Cross-Holdings | Green | Clean structure. No related-party transactions, no insider-controlled entities transacting with UCT, no asset migration patterns. |
| Capital Allocation | Yellow | 2018 M&A modestly overpriced (reflected in $151M goodwill impairment). Capex build poorly timed. No buyback discipline. New team expected to improve. |
| Compensation Alignment | Yellow-Green | 55% PSU weighting on new CEO comp is good. 3-year cliff vest is strong. Sign-on package was necessary to recruit. Specific hurdles not confirmed (need FY2025 proxy). |
| Credibility / Follow-Through | Red-Yellow | Prior management (Scholhamer era) is subject to a securities fraud class action for China demand statements. This is a real credibility mark. New management (Xiao era) is early but showing conservative guide-and-beat behavior. |
| Governance Quality | Yellow-Green | Board is well-composed with domain expertise. Class action is the key open governance issue. Edman as incoming Chairman is an upgrade. |
| Litigation / Enforcement | Red | Active securities fraud class action lawsuit (May 2024 – Feb 2025 class period). New management not implicated, but UCT as a company and potentially Savage as CFO are named defendants. Material, unresolved. |
| Overall Management Grade | C+ / B- | New team credible, old team’s credibility failure is unresolved. |
Green flags: - New CEO Xiao from Applied Materials is among the strongest credible hires UCT could have made for this company’s specific challenges - COO Wunar also from Applied Materials — deliberate discipline import - Board composition is strong — Maddock (Micron/Lam CFO), Seto (22 years at Lam Research), Edman (TTM/Applied Materials), Solomon (Amkor CFO) - No related-party transactions, no shell entities, no asset migration — clean governance structure - PSU weighting and 3-year cliff vest are governance-positive in compensation structure - Corporate structure is simple and standard for a multinational manufacturer - No SEC enforcement actions against any current executive
Yellow flags: - No open-market buying by new CEO (Xiao) — important to watch - Goodwill impairment ($151M, FY2025) reflects modestly overpriced 2018 acquisitions - CFO Savage’s continued role while being named in the class action period is a governance consideration (though standard to retain management through litigation) - Capex discipline was reactive, not proactive (built for $4B then retreated) - Board non-independence of Granger is a minor concern - CEO pay ratio 191:1 (notable but not unusual for global manufacturer with overseas workforce) - PSU hurdle details not yet publicly available — need FY2025 proxy to fully assess alignment structure
Red flags: - Active securities fraud class action lawsuit (class period May 2024 – Feb 2025). Allegations are specific and the 28% single-day stock drop on the disclosure event gives them credibility. Most such cases settle; the question is the size of the liability. This is not a current-management problem, but it is an unresolved corporate liability. - Prior CEO departed abruptly one week after the earnings event that triggered the class action. Timing of health-related departure is suspicious regardless of the actual cause. - No open-market insider buying at any level over the last 12 months — not a red flag in isolation but worth tracking.
Would you trust these people with your capital? The current management team — yes, with meaningful caveats.
James Xiao is a credible CEO from the right background. Robert Wunar brings the operational DNA UCT needs. The board, strengthened by Solomon (Feb 2025) and with Edman incoming as Chairman, has both the domain expertise and the financial oversight capability to govern effectively.
The unresolved securities fraud lawsuit — which covers the prior management era — is the most important outstanding issue. It creates a financial liability (potential settlement in the $20-100M range), a distraction for management attention, and a reputational cloud that will not fully clear until the case resolves. New investors are buying a company that is being sued for having misrepresented its China demand trajectory for nine months. That does not implicate the new team; it does implicate the corporate institution.
The absence of open-market buying by Xiao is worth revisiting. By Q3 2026, if the CEO has not made a visible personal investment in UCT stock, it is a yellow that should move toward red. Equity-only skin in the game — especially grants received as compensation — is weaker than cash put at risk.
For an investment position, the management picture is: acceptable and improving, with one material litigation tail risk that is priced into the stock only partially (if at all). The current 42x forward P/E does not appear to include a meaningful discount for the class action liability.